LV10538B - Method for testing of immunological binding substance in biological liquid and diagnostically remedy - Google Patents

Method for testing of immunological binding substance in biological liquid and diagnostically remedy Download PDF

Info

Publication number
LV10538B
LV10538B LVP-93-465A LV930465A LV10538B LV 10538 B LV10538 B LV 10538B LV 930465 A LV930465 A LV 930465A LV 10538 B LV10538 B LV 10538B
Authority
LV
Latvia
Prior art keywords
igg
specific
hjih
aggregates
mak33
Prior art date
Application number
LVP-93-465A
Other languages
English (en)
Other versions
LV10538A (lv
Inventor
Helmut Lenz
Ellen Missner
Werner Stock
Norbert Franken
Crance Mccarthy
Albert Rider
Harald Haug
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of LV10538A publication Critical patent/LV10538A/lv
Publication of LV10538B publication Critical patent/LV10538B/lv

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/824Immunological separation techniques
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/825Pretreatment for removal of interfering factors from sample
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125Digestion or removing interfering materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Description

LV 10538
CIIOCOE ΟΠΡΕΛΕΛΕΗΗΗ ΗΜΜΥΗΟΛΟΓΗΗΕΟΚΗ CBiBMBAEMOrO BEUļECTBA B EHOJIOrHHECKOfl atHUKOCTH H flHATHOCTHHECKOE CPE^CTBO
OĪIHCAHHE M3o5peTeHHe KacaeTca ycoBepmeHCTBOBaHHoro cnocoēa min onpe^ejieHHH HMMyHOJiorH4ecKH cBH3bmaeMoro nojiHBajieHTHoro eemecTBa b npncyrcTBHH no ΜεΗΒΐιιεή Mepe j3Byx επειίΗφΗΗεεκΗχ HMMyHOJiornHecKH cBH3biBaeMoro BemecTBa peaKTHBOB u b npncyrcTBHM ΗΗΓΗδΗΤΟρα flJIH KOMneHCanHH ΒρβΛΗΜΧ φΒΚΓΟρΟΒ B npo6aX CBIBOpOTKH KpoBH qejioBeKa, a Taoce npuro^Horo min 3τογο peaKTHBa.
HyBCTBHTejibHoe onpe^ejieHHe HMMyHOJiorHHecKH cB«3biBaeMbix BemecTB, Kax, HanpHMep, nojiHBajieHTHMx aHTHreHOB (πεπτΗΛΜ, προτβΗΗΗ, nojwcaxapnabi, BHpycbi, ēaKTepHH, επεηκφΗΗεοκΗε ιαιετκη)
ΠρΜ MCn0JIb30BaHHH flByX HJIH ΠρΗ ΗεοδΧΟΛΗΜΟΟΤΗ ēOJIblltelO KOJIHH8CTBa aHTHTBJI, KOTOpbIB HanpaBJteHbl npOTHB npOCTpaHCTBOHHO pa3JIHHHbIX aHTHrOHHbIX ίΐετερΜΗΗ3ΗΤΟΒ, H3BOCTHO B BHJC 2 HMMyHOpiWHOMeTpHqeCKOrO mm HMMyH03H3HM0MeTpH»ieCK0r0 CJlOHCTOrO aH&iiM3a (HMMyHoaHajiH3 c λβυμη yHacTKaMH). HanGojiee ynoTpe6HTejibHOH HBJiaeTca peajiH3auHH 3τογο H3BecTHoro cnoco6a onpenejieHHii, npuneM onpejiejMeMbiH aHTHreH (npoēa) HHKy6HpyeTca c noMombio nepBoro aHTHTejia, κοτοροβ hjih b TBepaoif φ33ε coe/iHHeHo c πρΗΓΟΛΗΗΜ MaTepHajioM-HocHTejieM, KaK, HanpHMep, οεφ3ρο33, arapo3a, rpy6oMKM H3 CHHTeTHHecKoro nojiHMepa h TOMy noaoēHoe, hjih HMeeTCH roMoreHHo, KaK, HanpHMep, 6ητηηηληροβ3ηηο b pacTBope, h c noMombio onpeaejieHHoro KOJinnecTBa BToporo hjih λρ>τηχ
MapKHpOBaHHbIX aHTHTeJI B 5ΚΗΛΚΟΗ φ33ε. ΟπείΙΗφΗΗΗΟΟΤΒ ΒΤΟρΟΓΟ Η npH Heo6xOflHMOCTH flpyTHX aHTHTeJI BblSHpaeTCH npeJinOHTHTeJIbHO TaKHM o6pa30M, Ητο oHa HanpaBJieHa προτΗΒ λρ>τηχ neTepMHHaHTOB onpenejiaeMoro aHTHreHa KaK nepBoe aHTHTejio, ητο6μ hckūkd^htL· KOHKypeHTHyio 6opb6y Mexjiy aHTHTejiaMH 3a τε xce caMbie MecTa npHcoeaHHeHHH κ onpeaeji«eMOMy aHTHreHy, TaK KaK 3thm 6biJia 6bi CHHJKeHa HyBCTBHTejibHOCTb npo6bi. KaK nepeoe, coenHHeHHoe b τεερΛΟΗ φ83ε hjih 6HOTHHHJiHpoBaHHoe, tbk η Βτοροε hjih npyroe HMeiOmeeCB B pacTBope MapKHpoBaHHoe aHTHTejio aoGaBJiaioTCH b H36bmce. CooTBeTCTByioiJUHft aHTHreH Μθ>κετ onpenejiHTbCH hjih nepe3 33φπκεΗροΒ3ΗΗ>το Ha nepBOM aHTHTejie hjih ocTaBinyiocH b pacTBope, HMMjmojiorHHecKH HecBH3aHHyio aKTHBHOCTb. B nocjiejiHeM cjiynae ΗεοδχοΛΗΜο jioāaBJiHTb onpeaejieHHoe KOjiHHecTBO MapKHpoBaHHbix BTOpbIX aHTHTeJI. Πο npHHHHe ΗεοβΧΟΛΗΜΟΗ επείίΗφΗΜΗΟεΤΗ flJIH HMMyHOJIOrHHeCKHX CJIOHCTbIX aHajIH30B HCnOJIb3yiOTCfl, B HaCTHOCTH, BbiBe^eHHbie H3 MOHOKJioHajibHbix aHTHTeji (MAK) coBepmeHHbie HMMyH0rjI06yjIHHbI IgG HJIH HX HMMyHOJIOrHHeCKH peaKTHBHbie φρΒΓΜβΗΤΜ (Fab, F(ab')2). Οαμκο κροΜβ τογο b sth npo6bi μοχηο BBOflHTb HMMyHOpeaKTHBHbie COCTaBHbie HaCTH, KOTOpbie BbIBOflflTCH H3 nojiHKJioHajibHbix aHTHTeji (PAK). LV 10538 ΧθΤΗ B OnHCaHHI>IX HMMyHOaH3JIH3aX C ΛΒΥΜΛ jmacTKaMH JUIH onpeflejiaeMbix aHajiHTOB Hcnojib3yioTca επειίΗφΗΗεεκΗε aHTHTejia, co 3Ha<IHTe;ibHOH HaCTOTOH nOHBJIHIOTCH npo6bI CbIBOpOTKH KpOBH HeJlOBeKa, KOTopbie Bbi3biBaiOT ΗεεπειίΗφΗΗεεκπε peaioiHH. riocjieaHHe npHBomiT κ ΟΙΙΙΗβΟΜΗΗΜ pe3yjIbTaTaM HCnblTaHHH C COOTBeTCTBeHHO OTflniaiOIHHMH nOCJieJICTBHHMH ĶJlSi TepaneBTHHeCKHX MeponpHHTHH. riOHBJieHHe ΗεςΠβΙΙΗφΜΗβΟΚΜΧ peaKUHH ΜΟΧΗΟ 06b5ICHHTb HMeiOmHMHCa B npo5e BemecTBaMH, κοτορωε tohho τβιοκε, KaK η οπρεΛεΛπεΜΗΜ aHajim (ποϋΗΒΒϋεΗΤΗΜή aHTHreH), cBH3biBaioT επείίΗφΗΗεεκκε HMMyHOnio6yjIHHOBbI8 peareHTbl (ΒρεΛΗΗε φβκτορω), ΟΚΗΆΚΟ B apyrax T04KaX B03jļ8HCTBHH. īl03T0My o6bIHHO K TaKHM HMMyHOaHajIH3aM ΠρεΒεΗΤΗΒΗΟ B h36wtkb flo6aBJi«K)Tca ΗεεπείίΗφΗΗεεκκε HMMyHorjio6yjiHHbi hjih φρΒΓΜΒΗΤΜ MMMyHOrJIo6yjIHHOB (KaK npaBHJIO, ρε% npH 3TOM Ηαετ o6 HMMyHorjio6yjiHHe C, IC) τεχ >κε bhūob χοιβοτηβιχ, ot KOTopbix npoHcxojHT επεκΗφΗΗεεκκε (G.M. Addison in Radio immuncassay and Related Procedures in medicine, Vol. I, 131-147 (1974); εΒροπεκεκΗίί naTeHT JVs 0174026). C MOMBHTa πρΗΜεΗεΗΗ» επευΗφΗΗεααιχ MOHOKJIOHaJIbHbIX aHTHT8JI, KOTOpbI8, KaK npaBHJIO, npOHCXOJIHT OT MbiniH, yKa3aHHoo ΜεροπρΗΗΤΗε no ycTpaH8HHio ποΜεχ b HMMyHoaHajiH3ax Tp86yBT 6ojibinoro KOJiHH8CTBa ΗεεπειίΗφΗΜεεκοΓο
MbllUHHOrO HMMyHOrJIo6yjIHHa IgG B φορΜε MbiniHHOŪ CbIBOpOTKH, MbiniHHoro acuHTa hjih H30jmpoBaHHoro MbiniHHoro HMMyHorjio6yjiHHa (πρΗΜερΗο 300-500 μκγ/mji; Clin. Chem. 32, 1491-1495 (1986)). HanpHM8p, b cootb8tctbhh c εΒροπεκεκΗΜ naT8HTOM Ns 0174026 ājiaronapa ao6aBK8 πρΗΜερΗο 30 μκγ/mji BajKHoro, ΗεεπειίΗφΗΊεεκοΓΟ MbllUHHOrO HJIH KpbICHHOrO HMMyHOrJIo6yjIHHa IgG K HMMyHOnpo6aM onncaHHoro rana tojibko β οπρε^ειιεΗΗΜΧ cbiBopoTKax h b oco6bL\ cjiyHaax (oTpHiiaT8JibHbix npo6ax) aocTHra8Tca nojiHaa κοΜπεΗεβιπίΗ HapymeHHH. OflHaKO npHIOTOBJI8HH8 MbllUHHOrO HMMyHOrJIo6yJIHHa Β MacniTa68 nopH^Ka KHJiorpaMMOB hcbo3mo>kho npn cyii^cTByiomHx 4 cero/iHa MeTOAax b 3Κ0Η0ΜΗ4εεκπ MHTepecHbix ycjiOBHax η κ TOMy xce Bbi3biBaeT KpHTHKy c 3ΤΗΊεεκΗΧ το^εκ 3peHHa.
BajKHbiM MeponpH3TneM &īih M36e>KaHHH noMex b HMMyHonpo6ax yKa3aHHoro rana hbjīh8toh πρΗΜεΗεΗΗε Fab-min F(ab')2~ Φρβγμοητοβ no MeHbmeH Mepe οληογο H3 npMMeHeHHbix b HMMyHonpo6e επεηπφΗΗεεκΗχ aHTMTeji. TeM caMbiM Bce epe^Hbie φ3κτορω b προβε, KOTopbie HanpaBJieHbi Ha Fc-qacra HMMyHonio6yjiHHa IgG (peBMaTHHecKue φ3κτορω, aHTH-Fc-MMMyHorjio6yjiHHbi, KaK HanpMMep, IgG M), ycrpaHHK)TCfl b το<ικε ετο bo3^ohctbhh Ha οληομ H3 επεηΗφΗπεεκΗχ peareHTOB h TaKHM o6pa30M Ηε HyxaaoTCH b KOMn8H8aiļHH.
OiiHaKO ΗεεΜοτρπ Ha Hcnojib30BaHHbiB επειίΗφΗΗεεκΗε ρε3ΓεΗΤΗ 3ΗΤΗΤεΛ, εΒΟδΟΛΗΗε ΟΤ φρΒΓΜεΗΤΟΒ Fc, ΗεΚΟΤΟρΜΧ CbIBOpOTKaX KpOBH *I8JIOB8Ka Β HMMyHOnpo6aX ΠΟΗΒΛΗΙΟΤεΗ HapyiU8HH«. 3τμ HapyiU8HHfl MOiKHO ΟδΐΗΟΗΜΉ HaJIHHHOM B CbIBOpOTKe cy6cTaHUHH, κοτορκε HanpaB,i8Hbi Ha φρΒΓΜεΗτω Fab hjih F(ab')2* B cootb8tctbhh c εΒροπείίεκΗΜ naT8HTOM N° 0083869 TaKH8 Βρε/ΐΗ^ε φ3κτορΜ 3ohm Fab pacno3HaiOTca TOJibKO Torjia, Koma ohh οχπε,πεΗΜ οτ Fc-qaoTH. B cooTBeTCTByK)mHx HMMyHonpo6ax sth φ3κτορω μογ>τ 6biTb yerpaH8Hbi nyT8M AOČaBKH HaTHBHbIX HJIH C8THaTbIX, ΗεεπεΗΗφΗΗεεΚΜΧ ΛΠΗ οπρεΛεΛπεΜΟΓΟ aHTHT8Ha φρ3ΓΜ8ΗΤ0Β Fab hjih F(ab'>2 (εΒροπείίεκΗΗ naT8HT N° 0083869). Πρπ stom arp8rHpoBaHHbie φρΒΓΜβΗΤΗ Fab hjih F(ab')2 o6Hapy5KHBaioT b 2-3 pa3a 6ο;ιεε BbicoKoe 3auiHTH08 ΛείίοτΒΗε no OpaBH8HHK) ε HaTHBHbIMH OOOTaBHbIMH HaOTHMH. HanpOTHB, nOJIHbI8 ΗεεπεηπφΗΗεεκΗε HMMyHonio6yjiHHbi IgG β εοοτΒετετΒΗΗ ε εΒροπείίεκΗΜ naTOHTOM N° 0083869 Ηε εποεοδετΒ^τοτ 3amHT8 οτ ΒρεΛΗΜχ φΒκτοροΒ β yKa3aHHbix HMMyHonpo6ax KaK β ηβτηβηοη, TaK η β arporupoBaHHOH φορΜε. ΚροΜε τογο, εποεοδ ΗΜεετ εγιΐίεετΒεΗΗΜίί HejļooTaTOK, 3aianoqaiomHHoa β τομ, μτο npn stom Hapaay εο επευηιφΗΗεεκΜΜΗ ajih οπρε,αειίίίεΜΟΓΟ aHTHroHa HMMyHonio6yjiHHOBbiMH poar8HTaMM τρε6γετε« 3HaiHTeJibHoe KOJiimecTBo ΒΗεοκοκ3<ίεετΒ8ΗΗΜχ LV 10538
Hecnem«ļ>HMecKHx HMMyHorjio6y;iHHOBbix peareHTOB, hto npHHOCHT c co6oii cymecTBeHHbie 3KOHOMHHecKne, a Taioice 3THHecKne npo6jieMbi. B COOTBeTCTBHH C 3TMM ĶJlii 3aiJUHTbI OT ΒρβΛΗΜΧ φΒΚΤΟρΟβ HCnOJIb3yiOTC5I, HanpMMep, no MeHbmeit Mepe b KOJiHHecTBe 100 μκγ/mji, OKa3aBiimecfl θφφεκτΜΒΗΗΜΗ arperMpoBaHHbie Hecneu^HMecKHe φρΒΓΜβΗΤΜ HMMyHOrao6yjIHHa, CB060ŪHbie OT φρ3ΓΜβΗΤ8 Fc. rio3TOMy b ocHOBe H3o6peTeHHH jiexMT 3ajaHa npe^ocTaBJieHHa b pacnopitaceHHe HOBbIX B03MOJKHOCTeft flJĪH KOMneHCaiIHH ΗεΟΠβηΗφΗΗβΟίΟΙΧ peaKUHft npM HMMyHOaHaJIH3aX C nOMOlIiblO conepx:amHX Fc φρΒΓΜβΗΤΜ. η οβο6οληβιχ ot Fc φρ3ΓΜεΗΤ0Β οπβηΗφΗ^εοκΗΧ peareHTOB ammen b tcanecTBe οπβιΐΗφΗΗβοκιιχ peaicraHTOB, 6jiaroaapa neMy b cbmopoTKax kpobh nejioBeica HajiejKHO ycTpaHHK>Tca HanpaBJieHHbie Ha nojiHbie HMMyHorjio6yjiHHbi IgG h Fab-hjih F(ab'>2· φρ^ΓΜβΗΤΗ BpeaHbie φ3κτορΒΐ, h KOTOpbie c yneTOM 3TH4eCKHX ΤΟΗβΚ 3ρβΗΗΛ flOĪTyCKaiOT SKOHOMHHeCKOe HCn0.1b30BaHHe ycoBepmeHCTBOBaHHbix τεοτοΒΒΐχ cHdeM.
B COOTBeTCTBHH c H3o6peTeHHeM 3Ta 3ajiaHa pemaeTca c noMombio cnoco6a jum onpe^ejieHHH HM\iyHOJiorHHecKH CB«3biBaeMoro BemecTBa b 6HOJIOrH4eCKOft JKHJIKOCTH nepeoro BH^a >KHBOTHbIX HJIH JIKD^eH B npHcyTCTBHH no MeHbineft Mepe j(Byx οπβΐίΗφΗΗεεκηχ jpm ημμ>ήολογηη6οκη CB«3biBaeMoro BemecTBa peaicraHTOB BTOporo Bima XCHBOTHbIX Η B npHCJTCTBHH HHTH6HTOpa ΚΪΙΆ KOMneHCaiJHH BpejHbIX φ3κτοροΒ nepeMeuiHBaiOT peaKUHOHHjno cMecb c* 0,1-50 mkt/mji ΗεοπβηκφΗΗεοκΗχ mm HMMyHOJiorHHecKH cBH3biBaeMoro BemecTBa, BbIBe^eHHbIX H3 MOHOKJIOHajIbHbIX HJIH nOJIHKJIOHajIbHbIX aHTHTeJI arperaTOB ετοροτο h/hjih TpeTbero Bima )κηβοτημχ. B KanecTBe HMMyHOJiorHHecKH cBH3bmaeMoro BemecTBa b nacTHocTH, Hcnojib3yioT TaKHe nojiHBajieHTHbie aHTHreHbi, xax nenTHHbi, npoTenHbi, noaHcaxapHHbi, BHpycbi, GaicrepHH h JipyrHe cnem^imecKHe KJieTKH hjih hx cocTaBHbie HacTH. B KanecTBe οπεηΗφΗΗεοκπχ peaicraHTOB ņjih cooTBeTCTBeHHo onpejiejmeMOH HMMyHOJiorHHecKH cB«3biBaeMoro 6
BemecTBa Moryr Hcno^tBOBaTbC» KaK ποληκλοη3λβημ8, TaK h MOHOKJioHajn>Hbie aHTHTena, npn stom npeano^THTejibHo KOMČHHMpOBaHHO HCnOJIb3yiOTCH MMMyH0rJI06yJIHHbI IgG H TaKHe HX HMMyHopeaKTHBHbie cocTaBHbie *iacTH, KaK Fab-ΗΛΗ F(ab')2· OparMeHTbi. Oco6eHHO npeanoHTHTejibHbiM ΗΒΛΗετεΗ Hcnojib30BaHHe #Byx ηλη npn Heo6xOHHMOCTH HeCKOJIbKMX ΟΠείίΗφΗΗεΟΚΗΧ peaKTaHTOB, H3 ΚΟΤΟρΜΧ no MeHbiuen Mepe οληη HBJiaeTCH Fab-ΗΛΗ F(ab')2· Φρ3γμ8ητομ h ocTajībHbie hbjihiotch επεηΗφΗΗεεκΜΜΗ p8aKTaHTaMH HMMyHorrco6yrcHHOB IgG. B ΚΒΗεετΒε ΗεεπεηΗφηηεεκΗχ min ΗΜΜ^ΟΛΟΓΗκεεκκ cBH3biBa8Moro B8in8CTBa arp8raTOB aHTHTeji mm KOMrreHcaiiHH HapymeHHit ηρεΛΠοητΗτεΛΒΗΟ Hcnojib3>TOTca arp8raTbi ΗεεπεηΗφΗΗεεκηε min ΗΜΜ}ΉΟΛΟΓΗΗεεΚΗ CB»3bIBa8MOrO BSIHBCTBa HMMyH0rJI06yJIHHbI IgG, ΟΟΟβεΗΗΟ np82tn04THT8JIbHbIM HBJIH8TCH aip8raT HMMyH0rJI06yjIHHa IgG, cocTOHiiiHfi H3 ΗεεπεηΗφΗπεεκοΓο H\iMyHor^o6y^HHa IgG η λρ>τοη MaKpOMO.TC8Ky.JIbI. ΠρΗ 3T0M ΠρεΛΠΟΗΤΗΤεΛΒΗΜΜΗ HB.TCHK)TCfl ΗεεπεηΗφηηεεκΜε HMMyHorno6y^HHbi, κοτορκε nponcxoaaT οτ τογο >κε caMoro Bima χηβοτηηχ, ητο h no M8HbW8H Μερε οληη H3 επείίΗφΗΗεοκΗΧ p8aKTaHT0B. B aaHHOM cjiyHa8 b KanecTBe MaKpoMo;i8Kyji npnronHbi, HanpHM8p, Fab-HJin F(ab')2· Φρβγμ8ητβι, τ.ε. cBo6oaHbie οτ Fc φρ3ΓΜ8ΗΤΗ HMMyHonio6y.rcHHa IgG, κοτορΒίε Moryr npoHcxoanTb οτ nojiynaeMbix οτ Mbiinn ηλη #pyroro Bnaa μοηοκλοηλλβηβιχ ηλη ΠΟΛΗΚΛΟΗ3ΛΒΗΒΙΧ ΛΗΤΗΤ8Λ, Ά TaiQK8 ΠρθΤ8ΗΗΒΙ (HanpHM8p, aTCb6yMHH), ΠΟΛΗ03Χ3ρΗΛΒΙ (HanpHM8p, aOKCTpaH) ΗΛΗ ΛΡ>ΤΗ8 paCTB0pHMbI8 Β Β0Λ8 ΠΟΛΗΜερΜ. ΚρθΜ8 ΤΟΓΟ, ΛΛΛ K0Mn8HCaiļHH Hapyni8HHH M0iyr ΗεΠΟΛΒ30ΒΒΤΒ0Λ ΓετερΟΠΟΛΗΜερΗ, K0T0pbI8 o6pa3yK)TCH, Η3ΠρΗΜ8ρ, Η3 MbiniHHoro HMMyHomo6yaHHa IgG c πομοιηβιο o6pa3yioinero M0CTHK0BbI8 CB83H HMMyH0HI06yTCHHa IgG Κρ>ΤΤΗΟΓΟ pOraTOrO CKOTa. Oco6eHHo πρεΛΠΟΗΤΗτεΛΒΗο ΗεποΛΒ3>τοτεΗ arperaTbi, coctohihh8 H3 ΜΟΛε^ΛΗ HMMyH0ΓΛ06yΛHHa IgG Η ΟΒΟδΟΛΗΟΓΟ ΟΤ Ρε-φραΚΗΗΗ φρ3ΓΜ8ΗΤ3 HMMyH0ΓΛ06yΛHHa IgG, npH48M KaK HMMyHOΓΛo6yΛHHbI IgG, LV 10538
TaK h CBo6oaHbie οτ Fc^paKiiHH φραΓΜεΗτω HMMyHonio6yjiHHa IgG ΠρΟΗΟΧΟΛΗΤ ΟΤ ΤΟΓΟ XCe Bma XCHBOTHbIX, 4T0 Η 0£HH H3 ΟΠεΗΗφΗΗεΟΚΚΧ peaicraHTOB. Taicne IgG/Fab-F(ab')2-noJiHMepbi o6Hapy>KMBaK>T ^a>Ke b τρπ pa3a Jiy4Uiee ββΗΟΤΒΗβ 3amHTbI ΟΤ ΒρβΛΗΒΙΧ φ3ΚΤ0ρ0Β, 4βΜ HHCTbie arperaTbi HMMyHorjio6yjiHHa. B 3aBHcnMocTH οτ HHHHBHj];yajibHOH npoObi CbIBOpOTKM &JIH ycneilIHOft 3aUļHTbI ΟΤ MemaiOIHHX φ3ΚΤθρθΒ Λ00Τ3Τ04Η0 0,1-50 mkt/mji cMemaHHoro nojiHMepa HMMyHorjio6yjiHHa IgG, ojiHaKo npejjnoHTHTejibHo pa6oTaioT c KOHueHTpaiļHHMH οτ 5 ķo 25 mkt/mji h OCOSeHHO npennOHTHTeJIbHO C KOHIļeHTpaLIHHMH OT 5 ĶO 10 mkt/mji, TaK KaK b čojibiHHHCTBe cjiy4aeB nojiHocTbio 3φφεκτΗΒΗΜΜ «BJineTca yxe 3Ha4HTejibHo MeHbiuee jioSaBJieHHe Hecnem^H4ecKHx arperaTOB HMMyHorjio6yjiHHa. B οοοτΒβτοτΒΗΗ c npeflnoHTHTejibHbiM BapnaHTOM ocymecTBjieHHH H306peTeHH4 HJIH KOMĪlSHCSmim ΒρεΛΗΜΧ φ3ΚΤ0ρ0Β B CbIBOpOTKaX KpOBH HejioBeKa Hcnojib3yiOTca HecneinKjMHecKHe roMonojiMMepHbie hjih reTeponojiHMepHbie arperaTbi HMMyHorjio6yjiHHa IgG hjih
IgG/Fab-F(ab')2-arperaTbi c MOJieKyjiapHbiM BecoM 320000 aajībTOHOB n 6ojiee. IIpu stom arperaTbi HMMyHorjio6yjiHHa IgG co^epxaT HMMyHorjio6yjiHH IgG BHfla, KOTopbift προΗοχοΛΗΤ no MeHbineft Mepe H3 ΟΛΗΟΓΟ H3 ΟΠβρΗφΗΗβΟΚΗΧ peaKTaHTOB, H OTHOCHTCfl K ΤβΜ )Ke nojucraccaM, mto h no MeHbineft Mepe οληη M3 οπείίΗφΗΗεααιχ peaicraHTOB. Πρκ stom npeanoHTHTejibHo Hcnojib3yK>TCH nojiHMepHbie npenapaībi HMMyHorjio6yjiHHa IgG c MOJieKyjiapHbiMH BecaMH οτ 320 Tbicaa ao 10 mhjuihohob aajībTOHOB, npiraeM KOMneHCHpyiomee B03AeftcTBHe oTHocHTejibHo HapyuiaioiHHX CbIBOpOTKy φΒκτοροΒ B03pacTaeT c jraejiHneHHeM MOJieicyjiapHoro Beca. OcoOeHHo npeanoHTHTejibHbiMH BapnaHTaMH ocymecTBJieHHH H3o6peTeHna HBJiaiOTCH HMMyHOaH3JIH3bI C JIByM5I yHaCTKaMH, C ^ByM« HJIH HeCKOJIbKHMH ΟΠβΗΗφΗΗβΟΚΗΜΗ ρβ3ΚΤ3ΗΤ3ΜH MbllUHHbDC HJIH KpbICHHbIX MOHOKJIOHaJIbHbIX 3HTHTeJI, H3 ΚΟΤΟρΜΧ ΠΟ MeHbUiett Mepe ΟΛΗΗ peaKTaHT HBJiaeTCH Fab-F(ab')2-4>ParMeHTOM H no MeHbiueH Mepe οληη H3 λρ>τηχ 8 peaicraHTOB «BjmeTca conepacamHM Fc^paKunio HMMyHonio6yjiHHOM IgG, b κοτορΗχ min KOMneHcaiļHH BpenHbix φ3κτοροΒ jioGaBJiaioTCH roMono^HMepHbie hjih reiepono^MMepHbie Hecnem^HHecKHe arperaTbi MMMyHorjio6yjiHHa IgG hjih IgG/Fab-F(ab')2-arperaTbi c MOJieKyjiflpHbiMH BecaMH 6ojiee 320000 jiajībTOHOB, npnneM conepacamnecfl b ΗβοπβΐίΗφΗΗεοκΗχ arperaTax HMMyHonio6yjiHHbi IgG h Fab-F(ab')2_ φρΒΓΜβΗΤΗ HBJiaiOTCa MOHOKJIOHaJIhHblMM H ΠρΟΗΟΧΟΛΗΤ H3 BHfla HJIH nojiKJiacca, κοτορωβ HBjraiOTCfl no MeHhineH Mepe οληημ H3 οπεηπφΗΗβοκΗΧ peaicraHTOB. Πρκ stom 6e3pa3JiHHHo, nojiynaeTca jih ΗεοπεηπφΗΗβοκΗΗ HMMyHorjio6yjiHH IgG hjih Fab-^parMeHT c noMombio aciļHTa, φβρΜβΗΤΒΐΐΗΗ hjih reHeranecKOH HHaceHepHH nyreM 3KcnpeccHH B MHKpOOpraHH3MaX.
ΠρΗΓΟΛΗΗβ ΠΟ Cn0C06y B COOTBeTCTBH H C H306peTeHHeM JUlfl KOMneHcaiļHH HapymeHHH nojiHMepH30BaHHbie HecneLnnļiHMecKHe MOJieKyjibi HMMyHorjio6yjiHHa hjih Hecnein#HHecKHe IgG/Fab hjih-F(ab')2_arPeraTbi .nojDKHbi βμβοληή>οη H3 npyroro BHaa, neM Te, H3 κοτορΒίχ προκοχοΛΗτ aHajiH3HpyeMaa npo6a. KaK npaBHJio, HMMyHOJiorHnecKHe cnoco6bi onpeaejieHHa Hcnojib3yioTca λπη aHajiH3a CbIBOpOTOK KpOBH HejīOBeKa C nOMOLUblO ΟΠβηΗφΗΗβΟΚΗΧ BbIBOflHMbIX OT MbllHH MOHOKJIOHaJIbHbIX aHTHTeJI HJIH HMMyHOpeaKTHBHbIX φρΒΓΜβΗΤΟΒ. OjiHaKo οπειίΗφΗΗβοκΗβ peareHTbi aHTHTeji Moryr TaioKe npoHcxo/iHTb ot Hpyroro Bima >κηβοτημχ. JU,o6aBJieHHbie juia 3ainHTbi ot Bpe^Hbix φ3ΚΤοροΒ ΗβοπείίΗφΗΗβοκΗε arperaTbi aHTHTeji Moryr cooTBeTCTBeHHO npoHCXoji;HTb οτ μηιιιη hjih KOM6HHaiļHH c HMMyHorjio6yjiHHaMH μμιπη hjih hx Fab-^parMeHTaMH jipyroro, otjihhhoio ot nepeoro BHaa χηβοτηηχ. HanpHMep, juih 3amHTbi ot HapyuiaiomHx φακτοροΒ b HMMyHoaHajiH3ax Μοιγτ Hcnojib30BaTbca reTeponojiHMepbi HMMyHorjio6yjiHHa μηιιιη/ HMMyHorjio6yjiHHa KpynHoro poraToro cKOTa (cmotph Bbirne), KOTopbie πρΗΜβΗίποται b KanecTBe οπεηΗφΗΗεοκοΓο peaKTHBa MOHOKJioHajibHbix aHTHTeji muihh hjih HMMyHorjio6yjiHHOB
MbllHH. LV 10538
Bjiaro^apa aoSaBKe b cootbctctbhh c H3o6peTeHHeM ΗεοπείίΗφΗ^εοκκχ arperaTOB IgG hjih IgG/Fab HJiH-F(ab')2-arperaTOB no cpaBHeHHio c HaTHBHHMM HMMyHorjio6yjiHHaMH IgG flocTHraeTca yBejiHHeHHaa Ha κο3φφΗΐιεΗΤ 20-1000 no cpaBHeHHio c ηβτηβηβιμη hjih arperHpOBaHHbIMH ΟΒΟδΟΛΗΗΜΗ OT Ρθ-φρ3Κ11ΗΜ φρ3ΓΜβΗΤ3ΜΗ
MMMyHorjio6yjiHHa IgG Ha κο3φφΗΐίβΗΤ 20-1500 hjih β τρκ pa3a 3φφεΚΤΗΒΗΟΟΤΒ KOMneHCaiIHH ΗεοπεηΗφΗΗβΟΚΜΧ peaKIIHH B HMMyHoaHajiH3ax no MeHbiiieii Mepe c HByMH cnem«ļ)HHecKHMH jouih onpe^ejuieMoro HMMyHoreHa peaicraHTaMH, H3 κοτορΗΧ no MeHbineH Mepe οληη BHBO^HTca H3 Fab HJIH-F(ab')2-φpaΓMeHτa. 3to yziHBHTejihHO, TaK KaK Hejib3H dbuio npejiycMOTpeTb, hto cojiepJKamHe HMMyHorJio6yjiHH IgG Hecnein^HHecKHe peaicraHTbi B HMMyHonpo6ax, β κοτορμχ ynacTByiOT cBo6onHbie ot Fc^paiaiHH οπειίΗφΗΗεοκΗε HMMyHor^o6yjiHHOBbie peareHTbi MOHOKJioHajibHbix hjih nojiHKJioHajibHbix aHTHTeji, Boo6me cnoco6cTByiOT KOMneHcaiiHH HanpaBJieHHbix Ha Fab HJiH-F(ab')2^parMeHTbi HapyuieHHH. TaK KaK b stom naTeHTe HenBycMbicjieHHO nozmepKHBaeTca, hto KaK HaTHBHbie, TaK h arperapoBaHHbie HMMyHorjio6yjiHHbi IgG He npoHBJiaiOT ηηκβκογο ycTpaHHiomero HapyineHH« 3φφβκτ3 npn yKa3aHHOM tūm HMMyHOJiorHHecKoM Tecie arrjnoTHHaiiHH h jūoSaBJieHHbie jjjir 3amHTbi ot HapyineHHft, KaK h ww cnei^HHecKoft arrjnoTHHaiļHH areHTbi flojuKHbi 6biTb οβο6οληη ot HMMyHorjio6yjiHHa IgG. ΗεοπεηΗφΗΗεοκΗΜ HMMyHorjio6yjiHH IgG caM no ce6e hjih c φpaΓMeHτaMH aHTHTeji, a Tarace c npoTeHHaMH, nojiHcaxapHaaMH hjih ūpyrHMH pacTBopHMMMH b Bo,ne MaKpoMOJieKyjiaMH 6jiaroaap5i B03jļeHCTBHio BbicoKoft TeMnepaTypbi Μοχβτ o6pa30BbmaTb MOCTHKOBbie CBH3H XHMHHeCKH HJIH HeKOB3JieHTHO Hepe3 ČHOpOJICTBeHHOe B3aHMOJieHCTBHe B COOTBCTCTBHH C H3BeCTHbIMH H3 JIHTepaTypbI MeTojiaMH. B jiioSom cjiyHae β βολημχ 6yφepHbIx pacTBOpax noBBJiBiOTCB pacTBopHMbie arperaTbi. XHMHHecKoe o6pa30BaHHe ceTHaTbix MOJieKyji mojkct ocymecTBJiBTbca, HanpHMep, c noMombio 10 ΓΟΜΟδΗφχΗΚΙΙΗΟΗ&πΒΗΜΧ HJIH ΓβΤβροδΗφγΗΚΙίΗΟΗΒΛΙίΗΗΧ XHMHHeCKHX COeflHHHTejIbHbIX ΒεΤΒβΗ (jIHHKepOB), C nOMOLUbK) npOTeHHOB HJIH aKTHBHpOBaHHoro JieKCTpaHa hjih nyreM caMoo6pa30BaHHH ceTHaTbix MOJieicyji HMMyHomo5yjiHHa IgG hjih hx h/hjih λρυγηχ οβο6ολημχ ot Fc-φρακηαΐΛ φρ3ΓΜεΗΤ0Β c noMoinbio KapāoaHHMH^a. KpoMe τογο, mojkho CBH3bIBaTb MOHOMepbl aHTHTejI C nOMOIliblO BOCCTaHOBJieHHH ΛΜΟγΛΒφΗΛΟΜ Η ΠΟΒΤΟρΗΟΓΟ OKHCJieHHH HJIH C nOMOlUbK) CaMOOKHCJieHHH ΗΧ JTJieBOJIHOH φρ3ΚΙΙΗΗ HJIH ΠΟΛΧΟΛΗΙΙΙβΗ MaKpOMOJieKyjIoft. B KaneCTBe XHMHHeCKHX COejJHHHTeJieH B paCHeT npHHHMaiOTCH, HanpHMep, CJIOJKHblH 3φκρ 6Hc(MajieHHHMHjxo)-MeTHJia, jiHMeTHji-cy6epHMHaaT, hhmhjihji-cy6epaT HHTapHoft KHCjioTbi, rjiyTapaHaJibaerHa, N-cyuHHHMHjniaHJi-3-(2-ΠΗΡΗΛΗΛΛΗΤΗ0)ΠΡ0ΠΗΗ3Τ, N-5-a3HaO-2-HHTpo6eH30HJI-CyiļHHHMMiI, N-cyuHHHMHmui(4-HoaapeTHJi)-aMHHo6eH3oaT hjih KOMČHHauMa MajieHHHMHaoreiccaHOHJicyuHHHMitaaTa h S-aneTHJiaHmapHii
MepKanTOHHTapHoft KHCJioTbi hjih aHajiorHHHbie coejiHHeHHH. IIojiyMeHHe aKTHBHpOBaHHoro aeKCTpaHa Μοχετ ocymecTBJiHTbc«, HanpHMep, H3 aMHHoneKCTpaHa onpeaejieHHoro MOJieKyjmpHoro Beca c noMombio MaJieHHHMHaoreKCaHOHJĪCynHHHMHaa, KOTOpbIH 3aTeM CBH3bIBaeTCfl c nojiyMeHHbiM προΗ3ΒθΛΗΗΜ MepKanToaijeTHJia ΗεεπείίΗφΗΗεαοιχ MojieKVJi HMMyHorjio6yjiHHa IgG. C noMombio 6ηοροληογο B3aHMOaeHCTBHH nOJīpa3yMKBaJIHCb B o6meM Η B nejIOM TaKHe CBH3H b TOM BHūe, B K3KOM OHH HMeiOTCfl, HanpHMep, B napax 6HOTHH/aBHJIHH (hjih CTpenTaBHaHH), ranTeH/aHTHranTeH-aHTHTejia, aHTHreH/aHTHaHTHreH-aHTHTejia, jiHraHa/cBB3yiomHH προτεκΗ (HanpHMep, THpOKCHH/THpOKCHHOCBH3yiOIHHfi npOTeHH), ropMOH/pepenTop. HaiyiexcaiuHH BapnaHT HcnojiHeHHH nojiyHaeTca nyreMno MeHbineM Mepe λβοηηογο 6HOTHHHJMpoBaHHii ΗεοπεηΗφΗΗεοκοΓο HMMyHorJio6yjiHHa IgG h zio6aBJieHHH CTpemaBHiiHHa hjih nyreM o6pa30BaHH« προη3βολημχ HMMyHorjio6yjiHHa IgG no MeHbuieH Mepe c jiByMH MOJieKyjiaMH jniroKCHreHHHa h o6pa30BaHHH MOCTHKOBbIX CBH3CH C MOHOKJIOHaJIbHblM HJIH nOJlHKJIOHajIbHblM aHTHTejioM aHTHjiHroKCHHa. Tohho Taoce πρηγολημμη «bjuiiotch LV 10538 arperaTbi, κοτορωβ ποηβληιοτοη b pe3yjibTaTe peaKUHH oČMeHa nojiHajib6yMHHa HejioBeica c MOHOKJioHajībHbiM aHTHTejioM aHTHaab6yMHHa HejioBena.
CooTBeTCTBehho nony4eHHbie cbipbie cMecH arperaTOB Moryr HenocpeacTBeHHo Hcnojib30BaTbCH nocjie ,mtajiH3a, mjih pa3,aejmTbCH, HanpHMep, C riOMOlUblO ΓβΛΒφΗΛΒΤρΒΙΙΜΜ Ha φρ3ΚΙΙΗΗ C yBeJI HHHBaiOmHMCH MOJieKyjlHpHbIM BeCOM H 3aTeM HCI10JIb30BaTbCfl Henocpe^cTBeHHo jopm KOMneHcaiiHH HapymaiomHx φΒκτοροΒ b HMMyHonpo6ax.
Ojihh H3 ao6aBjieHHbix b HcnbiTaTejibHyio cMecb οπβιΐΗφΗΗβααιχ peaicraHTOB, npejinoHTHTejibHO coaepjKamee Fc^paioiHio aHTHTejio HMMyHorjio6yjiHHa IgG, cBH3biBaeTC3 H3BecTHbiM cneuHajiHCTy cnoco6oM b ΤΒβρΛοϋ φ83β c MaTepHajioM-HOCHTejieM, KaK, HanpHMep, arapo3a hjih cHHTeTHHecKHe Tpy6o«nai h TOMy no,ao6Hoe, hjih HMeeTca, HanpHMep, b CBH3aHHOM C 6HOTHHOM ΒΜΛβ, Β ΧΗΛΚΟή φ33β. ĒCJIH HCnoJIb3yeTCH 6HOTHHHJiHpoBaHHoe nepBoe aHTHTejio, BHanajie o6pa3yeTc« κοΜίυιεκχ H3 aHTHreHa h MapKHpoBaHηογο BToporo οπβηηφΗΗβοκοΓο peaKTaHTa, KOTopbift 3aTeM b hjokhom MecTe cBH3biBaeTCH c MaTepHajioM-HOCHTejieM, ΠΟΚΡΜΤΜΜ CB«3bIBaiOIHHM 6HOTHH ΠρΟΤβΗΗΟΜ, HanpHMep, aBHJIHHOM HJIH CTpemaBHjiHHOM. OjiHaKo Hapany c sthm bo3mojkhm Taioce apyrHe BapHaHTbl npOBeaeHHH HCnblTaHHH C nepBbIM 6HOTHHHJIHpOBaHHbIM aHTHTejioM: aHTHreH BciynaeT b peaioiHio c GHOTHHHJiHpoBaHHbiM MOHOKJioHajībHbiM aHTHTejioM η b hjokhom MecTe hjih nocjie onpejiejieHHoro npe,«HHKy6aiļHOHHoro nepnojia cBH3biBaeTca c COejIHHHIOmeft 6HOTHH TBepflOft φ33θή H 3aTeM JIHHIb CBH3bIBaeTCfl c ΛΡ>τημ οπειίΗφΗΗβοκΗΜ peaicraHTOM. Hjih B03MoxceH cjiyqaH, Korūa BHaHajie aHTHreH BCTynaeT b peaioiHio co βτορμμ οπευ,ΗφΗΗεοκΗΜ peaicraHTOM h 3aTeM c 6HOTHHHJiHpoBaHHbiM aHTHTejioM. MapiaipoBKa BToporo h npn Heo6xoaHMOCTH apyrnx οπεηΗφΗπεοκΗΧ peaicraHTOB, b κοτορωχ pe»ib npejinomHTejibHO ΗΠ,ετ o CBo6oAHbix οτ Fc^paKmui φρΒΓΜβΗΤΒχ HMMyHorjio6yjiHHa IgG, ocymecTBJi«eTCH nyreM coe/uiHeHHa 12 c φερΜβΗΤΟΜ, c 4uiyopecunpyiomeīi, xeMHjiioMHHecuHpyiomeM hjih paaHoaKTMBHoii cy6cTaHUHeft. Cnoco6bi MapKHpoBaHHH πολο6ηογο poiia Πρ0Η3Β0ΛΗΙ>ΙΧ ΕΗΤΜΤβΛ CneiJHajIHCTy H3B80THbI, HanpHMep, H3 HCTOMHHKa
Ischikawa et ol .,J of Immunocssay 4 (1983) 209-327, h 3/iecb b aajībHeHuieM noacHeHHH He HjoKaaioTCB. /(pyrHM πρε,αΜετοΜ Η3θδρετεΗΗΗ hb^hiotch ΛΗΒΓΗοετκΜεεκΜε cpe^cTBa jum οπρε^εΛεΗΜΗ HMMyHOJiornMecKM cBH3biBa8Mbix nojiMBaji8HTHbix ΒειηεετΒ b HMMyHonpo6ax ε ^ByMH ynacTKaMH, KOTopbie conepxcaT onncaHHbi8 ΗεεπείίΗφΗΗεεκΗε arperaTbi aHTHTeji. /ļHarH0CTHH8CK08 Cp8flCTBO Hapiiay ε JIByMH HJTH ΓφΗ ΗεοδχΟΛΗΜΟεΤΗ H8CKOJIbKHMH ΟΠείΙΗφΗΗεεΚΗΜΗ aHTMT8JiaMH, ΟΛΗΟ H3 κοτορκχ «ΒΛΛετεΒ MoaeicyaoH HMMyHorjio6yjiHHa h no MeHbmeH Mepe ΟΛΗΟ CB06oflHbIM OT Fc^paiOUHH φpaΓMεHTOM HMMVHOrjIo6yjIHHa IgG, εο^ερχακτ 6yφεpHyϊO CHcreMy h onHcaHHbie ΗεεπειίΗφΗΗεεκΗε arperaTbi 3ΗΤΗτεϋ, a TaioKč πρκ Heo6xoaHMooTH apynre ο6μηηο Honoab3yeMbie ΒεΠΟΜΟΓΒΤεΛΒΗΗε BemeCTBa, KaK, Η3ΠρΗΜερ, yCKOpHT8^H ρεΒΚίΧΗΗ ΛετερΓβΗτω hjih cTa6HJiH3aTopbi. B KaaeoTBe npnroaHbix 6yφεpHbIX εκετεΜ Μοιγτ πρΗΜεΗΗΤΒεΗ, HanpHM8p, 20-60 MMOJib φοεφΒΤΗΜίί 6yφep (ΒΟΛοροΛΗΗϋ noKa3aT8Jib 7,0) hjih 50 MMOJib HEPES/100 MMOJib NaCl-6yφεpHaH εHετεMa (BoaopoaHbiH noKa3aT8jib 7,4). B ι^εετεε yoKopHT8aeH ρε3κιΐΗΗ 3aεεb b ρΒεπετ πρΗΗΗΜΒίοτεΗ, ΗΒπρΗΜερ, εyJIbφaτ aoKOTpaHa hjih nojiH3THJi8HrjiHK0Jib 6000 ao 40000, β KaaooTBe ΛετερΓεΗτοΒ, HanpHMep, τρπτοΗ χ-100, τβηη 20 hjih iuiypoHHK F-68 η β κ^ΗεετΒε πολχοληιηηχ oTa6HaH3aTopoB^eHoa, οκεΗππρΗΟΗ, xjiopaueTaMHH, MepTHojiaT η ap. Χ(ΗΒΓΗοετΗΗεεκοε ερε,αοτΒο εο^ερχΗΤ ΗεεπειίΗφΗΗεεκΗε arperaibi aHTHToa c MOJi8KyjiiipHbiMH Βεε3ΜΗ 320000 aanbTOHOB η 6θΛεε, ΠρεΛΠΟΗΤΗΤεΛΒΗΟ ao 10 MmUIHOHOB aaabTOHOB, Β KOHHCHTpaLIHH OT 0,1 ao 50 mkt/mji, πpεaπoι^τHτεabHo b KOHneHTpaiiHH ot 5 ao 25 μκγ/mji, h οεοδεΗΗΟ npoanoTTHToabHo b KOHUOHTpauHH ot 5 ao 10 μκγ/μλ. LV 10538 JļnarHocTHHecKoe cpeacTBO Μοχετ HMeTbca b φορΜε pacTBopa, hjih cyxoro XMMMHecKoro peaKTHBa, HaHeceHHoro Ha βπητηβειοιιιηη HOCHTeJIb, HJIH B OTKpbITOH IUieHKe.
JlMarHocTHHecKoe cpe^cTBO b cootb8tctbhh c Η3θ6ρετεΗΗεΜ b φορΜε pacTBopa, b κοτοροΜ npH Heo6xo^HMocTH ycTaHOBJieHo Tpe6yeMoe 3HaHeHHe pH, εο,αερχΗτ npejotnoHTHTejibHo Bce ΗεοδχοΛΗΜΗε jum Tecra peaKTHBbi. H3 coo6pax8HHH coxpaHH8MocTH npeanoMTHTejibHbiM Μοχετ 6biTb pacnpeaejieHHe Heo5xoiiHMbix jum TecTa peaKTHBOB no ^ByM hjih 6ojibineMy KOJiHtiecTBy pacTBopoB, κοτορκε cMeniHBaiOTca JiHiiib npn Henocpe^cTBeHHOM HccjienoBaHHH. Πρη stom HecymecTBeHHo, nonaioTca jih ΗεοπεηΗφΗΗεοκΗε arperaTbi ehthtoji pa3^ejibHo b Hajmexameft 6yφepHOH εκετεΜε, hjih/h c οληημ, hjih/h c o6ohmh, hjih λρ>τημη οπειίΗφΗηεοκΗΜΗ aHTHTejiaMH. ^jih nojiyqeHHa HHamocTHHecKoro cpeacTBa b φορΜε τεετ-uiHHbi BnHTbiBaiomHH HocHTejib, npoflnoHTHTejibHo, φιυΐΒτροBajībHaa 6yMara, U0JUiK)JiO3a hjih nponec εκΗτετΗΜεεκοΓο BOJioKHa προπΗΤΗΒθετεΗ paCTBOpaMH H806X0flHMbIX, 06bIHH0 npHM8HH8MbIX JUM. nOJiyHeHHfl τεετ-ihhh ρεΒκτΗΒΟΒ b πειχο πετγ^κχ pacTBopHTOjiax, Kax, HanpHMep, Boaa, MBTEHOJI, 3TaHOJI HJIH aiJ8TOH. 3Τ0 ΜΟΧ8Τ OCJOItOCTBJIHTbCH 3a OJIHy onopaiiHK) προπΗτκΗ. OjiHaKo nacTo iiejiecoo6pa3HO npoBo^HTb nponHTKy B H8CKOJIbKO OnepaiHHH, ΠρΗ^εΜ HCnOJIb3yiOTCH paCTBOpbl, κοτορκε εοοτΒετετΒεΗΗο coaepxaT aacTb Φρεκιιηη ζΐΗΕΓΗοετίί'ίεεκοΓο cpoflCTBa. /Ļia nojiyH8HHa HHarHocTHH8CKoro cpojucTBa b φορΜε τεετ-uiHHbi Μοχετ cjiyxHTb κροΜε τογο oTKpbiTaa ruieHKa, b κοτοροϋ Hap*my c ruteHK006pa30BaT8Ji8M η ΠΗΓΜεΗΤΕΜΗ εο^ερχΕτεπ επεκΗφΗ^εεκπε aHTHT8Jia hjih φρΕΓΜεΗτκ, οπκεΕΗΗΒίε ΗεεπειίΗφιΐΗεεκΗε arp8raTbi airorreji (φρΕΓΜεΗτοβ) Hazyiexamaa 6yφεpHaa CHdeMa h npoaHe ο6μηηο πρκΜεΗΛεΜκε jum jļHaraocTHHBCKoro cpojiCTBa jioēaBOHHbio Maiepnajībi.
ΓοτοΒκε T8CT-6yMara hjih τεετ-ιυιεΗΚΗ Moryr Hcnojib30Baibca xax ΤΕΚΟΒΜε HJIH HaKJI8HBaTbCH Η3ΒεεΤΗΗΜ Cnoeo60M Ha IUI8HKy-H0CHT8JIb, HJIH np8fln04THT8JIbH0 3an8HaTbIBaTbCH CHHT8THH8CKHMH Μ3ΤερΗ3ϋ3ΜΗ H 14
MeJIKOHMeMCTLIMM 06ΤΚ3ΜΗ B COOTBeTCTBHH C Π3Τ6ΗΤ0Μ ΦΡΓ JV° 2118455 h coejjHHHTBCH c nccjie,ayeMOH *JiaKocTbio Tejia (HanpHMep, KpoBbio, IUia3MOH, CbIBOpOTKOH). M3o6peTeHHe πρηγο^ηο ajih onpe/iejiemia ecex aHTHreHOB no MeHbmeH Mepe c ^ByMH aHTHreHHbiMH ^eTepMHHaHTaMM. ĪIpuMepaMH 3ΤΟΓΟ HBJIHIOTCH THpCOTpOnHH (TSH), KapiļHH03M6pH0HaJIhHbIH ΒΗΤΗΓεΗ (CEA), BHpycbi renaTHTa (noBepxHocTHbift aHTHreH rnnaTHTa B, HBS), Ι-φβτοπροτεΗΗ (AFP), nejiOBenecKMH χορΗθΗΓθΗ3ϋθτροπΗΗ (HGG), JIIOTeHHH3HpOBaHHbIM ΓΟρΜΟΗ (LH), φOJUIMKyJIflpHOCTHMyJIHpyK)l^IH¾ ΓΟρΜΟΗ (FSH), β2 -MHKponio6yjIHH, KMCJiaH ΠρθΟΤ3Τ3φθθφ3Τ333, npOJiaKTHH, φβρρΗΤΗΗ H HHCyjIHH.
Hajiee H3o6peTeHHe noacHHiOT HiDK£CJie,ayiomH8 npuMepbi.
IlpHMep 1
ļlojrv^eHHe MOHOKJiOHajībHoro arperaTa μμβιηηογο HMMVHorjio6yjiHHa IgG
ITVTeM “CUIHBaHHa” C OMo6HOd>VHKllHOHaJIl>HMM peaKTHBOM
MoHOKJioHajībHbift HMMyHorjio6yjiHH MAK33-IgG (6ojiee 95% ηηοτμη; no^KJiaccoBbift cocTaB K, γ I; επειίΗφΗηΗοσπ, aHTHKpeaTMHKHHa3a) H30jmpyeTca H3 acueTunecKOH jkmukocth c noMombio oca*meHHa cyj^aia aMMOHna h χροΜΒτοιρβφΗΗ Ha hohhoo6m8hhhko DEAE (cmotph: A. Johnstone and R. Thorpe, Immunochemistry in practice Blackvell Scientific Publications, 1982, ετρ. 44-45. 50 μγ HMMyHorao6yjiHHa IgG pacTBopaioT b 3 mji 0,025 MOJiapHoro 6HKap6oHaT/Kap6oHaTHoro 6yφφεpa c βολοροληημ noKa3aT8JteM 9,5.B 3tot pacTBop BbinycKaioT πκπετκοή 17 mkji 12,5-προηεΗΤΗΟΓΟ pacTBOpa rayTapaHajibaeniaa n HHKy6HpyioT β τεπεΗηε 2 nacoB npn Te\in8paType 25°C. 3aTeM pacTBop oxjiaxcaaeTca β πε/ρihom Β3ΗΗε h c noMombio 50 ΜΜΟϋεη TpHTaHOJiaMHHOBoro 6yφεpa ycTaHaB/iHBa8Tca βολορολημη noKa3aiejib 8,2. B stot pacTBop ;io6aBJiaK)T 0,6 mji LV 10538
cBeacenpHroTOB/ieHHoro pacTBopa GoprmīpaTa HaTpHh (8 μγ GopruapaTa HaTpM3/l mji 6naecTMJiJiHpoBaHHoft βολμ) η ΗΗκγδΗργιοτ b TeneHHe nocjiejiyiomHX 2,5 qacoe πρκ TeMnepaType 0°C. Hepe3 16 nacoB jmajiH3a npn TeMnepaType 0-4°C okojio 10 MMOJieii φοοφΒΤΗοΓΟ 6>Tļ)epa c ΒΟΛοροΛΗΜΜ noKa3aTejieM 75, conepacamero 0,2 M NaCl, yjiajiinoTCH
H36bIT04Hbie peaKTHBbl. /J,MajIH3aT ΠγΤβΜ yjībTp^HJIbTpaUHM KOHueHTpHpyeTCH λο oGibeMa 1,25 mji. Hacib stoio KOHiļeHTpaTa (cbipofi cMecM) Hcno^b3yeTCH HenocpejicTBeHHo ūjir ycTpaHeHHH HapymaiomHX φΒΚΤΟρΟΒ; 1,0 MJI XpOMaTOIļ^HpyeTCH C riOMOIUbK) rej^HJībTpaiiHOHHoft kojiohkh c HanojiHHTejieM AcA22(LKB). Pa3Mep kojiohkh 2 x 40 cm; pa6oHHft δγφβρ 10 MMOJieū φοοφΒΤ3/100 MMOJieft NaCl c βολορολημμ noKa3aTe;ieM 7,5. 3.rcioaT kojiohkh HccjiejiyeTCiī c noMoiubio yjibTļ^HOJieTOBoro MOHHTOpa npn 280 hm Ha cojjepacaHHe npoTeHHa h φρΒκιΐΗΟΗΗργετοΗ. <t>paKUMH Bcero co^epacamero προτβΗΗ 3JH0HH0HH0IO yHaCTKa o6l>ejIHHJnOTCH B 4 rpynnbl C OJIHHaKOBblM oGlbeMOM. ΠγτεΜ KaJIH6pOBKH ΓεΛΒΧρθΜ3ΤΟΓρ3φΗιΙ60ΚΟΗ KOJIOHKH C noMonibK) προτβΗΗΟΒ H3Becraoro MOJieKyjiflpHoro Beca c rpynnaMH Moryr 6biTb conpjDKeHH ynacTKH MOJieKyjiapHoro Beca 160000-400000, 400000-1000000, 1-2 mjih. h 2-10 mjih najībTOHOB. īlocjie KOHii;eHTpHpoBaHH« rpynn λο KOHueHTpaiiHH npoTeHHa okojio 2 μγ/mji arperaratie pacTBopbi HMMyHorjio6yjiHHa IgG pa3JiHHHbix ynacTKOB MOJieKyjiiipHoro Beca MOiyr Hcnojib30BaTbcx oji% ycTpaHeHHa HapymaioiiiHX φακτοροΒ. ΠοΗΜβρ 2 nojmieHHe MOHomioHajībHoro arperaTa μμιιιηηογο HMMVHorjioGvjiHHa πυτθμ “cniHBaHHfl” C reTePoGt^VHKUHOHaJIhHMM peaKTHBOM. a) riojiyHeHHe MAK33-IgG-MH (MajieHHHMHjioreKcaHOHJi-MAK33-IgG).
10 μγ MAK33-I C pacTBopaiOTCH b 4 mji 30 MHJiHMOJiapHoro φοΰφατΗΟΓο 6γφβρ8 c pH=7,l. K 3TOMy pacTBopy πΗπετκοίί jioGaBJiaioT 16 20 mkji (4 mkmjih) 0,2 MOJiapHoro pacTBopa MajieHHHMmioreKcaHOMJicyuHHHHMiiaaTa b flHMemiicyj^ooKcmie. PeaKUMOHHaa CMecb HHKy6HpyeTCH b TeaeHHe 1 aaca πρκ TeMnepaType 25°C, 3aTeM b TeHeHHe 16 HacoB οκοπο 10 MMOJiefi φοοφ3ΤΗθΓθ 6yφepa c pH=6,l, co^epMcamero 50 MMOJieii NaCl, HKajiH3npyeTca πρκ TeMnepaType 0-4°C. nojiyHaiOT 4,45 mji pacTBopa c 22 μγ MAK33-IgG-MH/MJi. b) FIojiyHeHHe MAK33-IgG-SAMS ( S-auemiMepKanTocyuMHHJi-MAK33-IgG) 100 μγ MAK33-IgG, pacTBOpaiOTca b 4 mji 0,1 MOJiapHoro φοεφ3ΤΗθΓο 6yφepa c BojiopojiHbiM noKa3aTe;ieM 8,0. K 3TOMy pacTBopy πκπετκοΗ AoēaBJiaiOT 40 mkjī 0,25 MOJiapHoro pacTBopa S-aueTMJiMepKanToaHrHiīpma HHTapHOM kmcjiotu b ΛΗΜετιυ^;ΐΒφοκοΗαε. PeaKiiHOHHaa CMecb HHKy6HpyeTca b TeaeHHe 1 naca ripu TeMnepaType 25°C, 3aTeM b TeaeHHe 16 nacoB okojio 10 mmojich ΦοοΦβτηογο 6yφepa c pH=6,l, cojiepJKainero 50 MMOJieft NaCl, jiHajiH3npyeTCH πρκ TeMnepaType 0-4°C. IIojiyHaiOT 4,45 mji c 21,8 μγ MAK33-IgG-SAMS/MJi. c) “CuiHBaHHe’’ MAK33-IgG-MH c MAK33-IgG-MS (MepKanTOCHUHHHji MAK33-IgG). 50 μγ MAK33-IgG-SAMS pa36aBJiaiOT λο KomieHTpaijHH 15 μγ/mji b 25 MMOJiapHOM φοεφΒΤΗΟΜ 6yφepe c pH=6,5, conepacameM 2 mmojih 3THJieao,HaMHHTeTpaaLieTaTa (6yφep A). K 3TOMy pacTBopy ΠΗπετκοίί floOaaiHioT 75 mkji 1 MOJiapHoro pacTBopa rmīpoKCHJiaMHHa h HHKy6HpyiOT CMecb b TeaeHHe 20 μηη πρκ TeMnepaiype 25°C. 3 mji 3τογο pacTBopa c 44 μγ MAK33-IgG-MS pa36aBJiaioT 6yφepoM A no 6,0 mji. B stot pacTBop noOaBJiaioT 4 mji pacTBopa c 88 μγ MAK33-IgG-MH. CMecb HHKy6HpyeTca b TeaeHHe 40 mhh ripu TeMnepaType 25°C, 3aTeM jpia oOpbiea peaKUHH “cuiHBaHHa” LV 10538 pa36aBjmeTCH ao 2 MMOJieft UHcreHHOM. ITocjie aajībHefimeft 30-μηη>τηοη HHKy6auHH npH TeMnepaType 25°C aoOaBJiiieTCH ao 5 MMOJieft N-MeTHJiMajieHHHMim h pacTBop BbmepjKHBaeTC» b TeneHHe 1 naca npn TeMnepaType 25°C. PeaKUHOHHbiH pacTBop aHajiH3HpyeTca OTHOCHTejibHo 10 MMOJieft φοοφ3ΤΗθΓθ 6γφερ3 c pH=7,5, coaepacamero 0,2 mojia NaCl. ^HajiH3aT c noMombio yJIbτpaφHJIL·τpa^HH KOHiieHTpHpyeTCH ao KomjeHTpauHH npoTeHHa 35 μγ/mji h njrreM ueHTp^yrHpoBaHHa ocBo6oxiiaeTCH ot Heāojibinoft μύτη. TnnHHHoe pacnpeaeaeHHe MOJieKyjiapHbix BecoB aJia TaKoro jļHajiH3aTa (cbipoft CMecn) arperaia MAK33-IgG noKa3biBaeT Φηγ. 1. ArperaTHaa cMecb MoaceT Hcnojib30BaTbCH HenocpeacTBeHHO hjih nocjie pa3aeaeHHa Ha φρ3ΐαΐΗΗ MOJieKyjiHpHbix BecoB (nyreM χροΜοτοιρ3φΗΗ AcA22, KaK b npHMepe 1) aJifl ycTpaHeHHa HapyuiaiomHX φακτοροΒ. ΠρΗΜβρ 3 ĪIojrvMeHHe aroeraTa MAK33-IgG imreM “cuiHBaHHg” c noMonibio a.MHHoaeKCTPaHa а) riojiyHeHHe S-aueTHJīTHoaueraii-aMHHoaeKCTpaHa 100 μγ aMHHOneKCTpaHa (aeKCTaH T40, φ3ρΜ3ΐΐΗΛ; 28 aMHHorpynn/MOJieKyjuipHbift Bec 40000) pacTBopjnoTca b 4 mji 30 MMOJiapHoro φοϋφΒΤΗΟΓΟ 6yφepa c pH=7,l. K 3TOMy pacTBopy mmeTKoft aoOaBJiaiOT 0,25 mji 0,2 MoaapHoro pacTBopa S-aiieTHJiTHoaueTHJicyiļHHHMHji;aTa b ^HMeτHJIcyJIbφoκc¾^e. PeaiaiHOHHaa cMecb HHKy6HpyeTCH b TeaeHHe 1 Haca npH TeMnepaType 25°C, 3aieM jiHajiM3HpyeTCH OTHOCHTejibHo 10 MMOJieft φοοφΒΤΗΟΓο 6yφepa c pH=6,l coaepjKamero 50 MOJieft NaCl. Bbixoa cocTaBjiaeT 90 μγ S-aueTHJīTHoaiieTHji-aMHHoaeKCTpaHa b 4,5 mji pacTBopa.
б) “CuiHBaHHe” MAK33-IgG-MH c THoaijeTHJi-aMHHoaeKCTpaHOM 2mji pacTBopa c 20 μγ/mji S-aueTHJīTHoaiieTHji-aMHHoaeKcipaHa OCTOPOJKHO C IIOMOmbK) 0,1 MOJIHpHOrO NaOH ΛΟΒΟΛΒΤ ΆΟ pH=6,5 H 18 floGaB-TjnoT 3THJieHiiHaMMHTeTpaaueTaT no 2 mmojich. K 3TOMy pacTBopy ΠΗπετκοίί aoGaBJiHioT 40 mkji 1 MOJiapHoro pacTBopa nmpoKCHJiaMHHa h HHKy6HpyiOT b TeneHHe 20 mhh πρκ TeMnepaType 25°C. 3aTeM pacTBOp pa36aBJUHOT 25 MOJiapHbiM φοφητΗΜΜ 6yφepoM c pH=6,5 no 6,8 mji h noGaBnniOT 7,2 pacTBopa c 158,4 MAK33-IgG-MH (nojiyHeHHe,KaK b npHMepe 2a). Ilocjie 30 mhh HHKy6aijHM npH TeMnepaType 25°C κ peaiaiHOHHoii cMecn noāaBniiioT hhctchh no 2 mmojich h nocjie 30 mhh flonoJiHHTejibHo N-MeTHJiMajieHHHMHa no 5 MMOJieH. Ilocjie najībHeHiueH HHKy6auHH b TeqeHHe οληογο Haca npn TeMnepaType 25°C nojiHMepH3aT nHajiH3HpycTcs oTHOCHTejibHo 10 MMOJieii φοοφητΗΟΓΟ 6yφepa c pH=7,5/50 MMOJieii NaCl. riocjie OTnejieHHH n;eHqH«ļ)yrHpoBaHHeM cjiaGoft MyTH nojiyHaioT 19,5 mji pacTBopa MAK33-IgG-neKCTpaH-arperaTa c conepacaHHeM npoTeHHa 7,1 μγ/mji. ΠρΗΜβρ 4
IIojrvgeHHe aroeraTa MAK33-IgG πντβΜ “cniHBaHHa” c HMMVHorjioovjiHHPM
κρυπηογο poraToro CKOTa IgG a) riojiyHeHHe HMMyHorjio6yjiHHa IgG-ΜΗ KpynHoro poraioro CKOTa 100 μγ nojiHKJioHajībHoro HMMyHorjio6yjiHHa KpynHoro poraioro CKOTa npeo6pa30BbiBaiOTCfl no aHajiorHH c npHMepoM 2a c noMombio 4 MHKpoMOJieft MajieHHHMHnoreKcaHOHJicyiiHHHMHnaTa. Bbixon cociaB.iHeT 4,45 mji pacTBopa c 22 μγ HMMyHorjio6yjiHHa KpynHoro poraToro CKOTa IgG-MH/MJi.
b) riojiyHeHHe MAK33-SATA (S-aueTHjiTHoaneTHji-MAK33-IgG) 100 mt MAK33-IgG pacTBopaioTca b 4 mji 30 MMOJinpHoro φοΰφητΗΟΓΟ 6yφepa c pH=7,l. K 3TOMy pacTBopy ΠΗπβτκοίί noOaBnaioT 20 mkji (mkmojih) 0,1 μοιιηρηογο pacTBopa S-aueTHJiTHoaueTHJicyiļHHHMHaaTa b ηπΜετιυκ^ηΒφοκοΗηε. PeaKUHOHHaa cMecb HHKy6HpyeTCii b TeneHiie 1 Haca npH TeMnepaType 25°C, 3aTeM b TeneHHe 16 nacoB nHajm3HpyeTCH LV 10538 πρκ TeMnepaType 0-4°C OTHOcHTejibHo μμοληρηογο φοεφατΗΟΓΟ δγφβρα c pH=6,l/50 MMOJI6H NaCl. nojiyqaiOT 4,45 mjī pacTBopa c 22 μγ MAK33- IgG-SATA/MJi. c) “CuiHBaHHe” THoauemn-MAK33-IgG c HMMyHonio6yjiHHOM KpynHoro poraToro cKOTa IgG-MH. 50 μγ MAK33-IgG-SATA pa36aBjmiOTCfl 25 μμολλρηημ φθθφ3ΤΗΗΜ δγφβρΟΜ C pH=6,5, COaepiKamMM 2 MMOJIflpHblH 3TmieHaHaMHHTeTpaaueTaT (δγφβρ A) ao KOHueHTpaiļHH 15 μγ/mji. K 3T0My pacTBOpy ΠΗπετκοή ao6aB.TjnoT 75 mkji 1 MOJiapHoro pacTBopa rnapoKCMJiaMMHa μ ΗΗκγδκργιοτ b TeHeHne 20 mhh. πρκ TeMnepaiype 25°C. K 3 mjī 3τογο pacTBopa c 44 μγ THoaueTHJi-MAK33-IgG ao6aBJiflK)T 4 mjī pacTBopa c 88 μγ HMMyHorjio5yjiHHa Kpyimoro poraToro CKOTa IgG-MH h HHKy6HpyiOT b Te^eHHe 25 mhh πρκ TeMneparype 25°C. ΪΧκά o6pbma peajoiHH “cniHBaHHH” ao6aBJiHeTCH 3aTeM UHcreHH ao 5 MMOJieH h nocjie 30 mhh HHKy6auHH πρκ 25°C HoaaijeTOMHa ao 5 MMOJieii. Ilocjie aaabHeiiiiieft HHKy6aiiHH b TeqeHHe 1 qaca npn TeMnepaType 25°C pacTBop jiHajiH3MpyeTCH b TeneHHe 16 nacoB πρκ TeMnepaiype 0-4°C OTHOcHTejibHo 10 MMOJiapHoro φοοφΒΤΗΟΓο δγφβρΒ c pH=7,5 coaepxcamero 50 MMOJieii NaCl. Ilocjie ιιεΗτρΗφ>ΤΗροΒ3ΗΗίΐ AHajiH3aTa nojiyHaiOT 8,9 mjī arperaia HMMyHorjio6yjiHHa KpynHoro poraToro CKOTa MAK33-IgG c KOHueHTpaiiHeH npoTeHHa 13 μγ/μλ. IIpHMep 5
Πο.τνΜβΗΗβ arneraTa MAK33-ļgĢ “cuiHToro” c πομοιιιμο MAK33-Fab a) riojiyMeHHe MAK33-Fab SATA 200 μγ MAK33-IgG paciueiuiaioTca c noMombio nanaHHa Ha Fab/Fc h MAK33-Fab H30JiHpyeTCH H3 cmcch nyreM xpoMaτoΓpaφHH Ha DE52 uejunojio3bi (eaTMaHCKaa 6yMara) (MeToabi cmotph b HCTOMHHKe: A. 20
Johnstone and R. Thorpe, Immunochemistry in practice Blackvell Scientific Publications, 1982, CTp. 52-53).Βμχοιι cocTaBJiaeT 95 μγ MAK33-Fab b BHne οπειίΗφΗΗεοκοΓο Jinc^HJiH3aTa. 50 μγ MAK33-Fab pacTBopaiOTca b 2 mji 30 MMOJiapHoro φοεφΒΤΗΟΓΟ 6>^epa c pH=7,l. K 3TOMy pacTBopy ΠΗΠβτκοή flo6aBJiaiOT 30 mkji (3 mkmojih) 0,1 MOJiflpHoro pacTBopa S-aueranTHoaiieTHJicyiiH-HHMuaaTa b jih MeτHJϊcyJIbφoκcHJ^e. PeaKUHOHHan cMecb HHKy6HpyeTc« b TeHeHMe 1 Mača npH TeMnepaType 25°C, 3aTeM b TeMeHHe 16 Macoe πρκ TeMnepaTye 0-4°C awajiH3HpyeTCH OTHOCHTeJibHO 10 MMOjmpHoro φοοφ3ΤΗθΓθ 6yφepa c pH=6,l, conep^amero 50 MMOJieft NaCl, 2 mmojih 3THJieHHHaMHHTeTpaaueTaTa. IIojiyHaioT 2,6 m/i pacTBopa c 18,5 μγ MAK33-Fab-SATA/MJi. b) "CniHBaHHe” MAK33-IgG-MH c THoaueTHJi-MAK33-Fab 30 μγ MAK33-Fab-SATA pa36aBJi5noTca 25 MMOJiapHbiM φοοφ3ΤΗΗΜ 6yφepOM c pH=6,5 ķo KOHueHTpaiiHH 15 μγ/mji. K 3T0My pacTBopy ΠΗπετκοή ao6aBJunoT 50 mkji 1 MOJiapHoro pacTBopa rmpoKCHJiaMHHa h HHKy6HpyioT b TeMeHHe 20 μηη πρκ TeMnepaType 25°C. B 1,5 mji 3Toro pacTBopa c 22 μγ THoaiieraji- MAK33-Fab aoOaBJiaeTCH 55 μγ MAK33-IgG-MH (nojiyMeHHe, KaK b npHMepe 2a) h 3Ta HcxojiHaii CMecb pa36aBJiaeTca GnjiHCTMJiJiHpoBaHHoii bojiom λο o6mero o6beMa 10 mji HHKy6HpyeTCfl b TeMeHHe 35 μηη πρκ TeMnepaType 25°C h 3aieM jvm o6pbiBa peaiciiHH “cmHBaHHH” bmbojihtch c noMonibio
UHCTeHHa no 5 MMOJieii. Ilocjie 30 μηη πρκ TeMnepaType 25°C
Ao6aBJiaeTca N-MeTmiMajieHHHMHji no 5 MMOJieii h BHOBb CMecb HHKy6HpyeTc» b TeMeHHe 1 Mača πρκ TeMnepaiype 25°C 3aTeM peaKUHOHHbiH pacTBop /iHajiM3HpyeTCH b TeMeHHe 16 nacoB πρκ TeMnepaType 0-4°C OTHOCHTeJibHO 10 MMOJiapHoro φοοφ3ΤΗοπ> 6yφepa c pH=7,5, coaepacamero 0,1 mojihphmh NaCl. flocjie υεΗτρΗφ>ΤΗροΒ3ΗΗΗ LV 10538 nojiyqaioT 12,8 mji CBeTJioro pacTBopa c 5,3 μγ arperaTa MAK33-IgG-Fab/ivui. IIpHMep 6
IlojrvMeHHe arperaTa MAK33-IeG ιτντβΜ “ciDHBaHHfl” c πομοιμμο 6hothh / CTpenTaBHJMHa
a) riojiyHeHHe ČHOTHHHJiHpoBaHHoro MAK33-IgG 50 μγ MAK33-IgG b 2,5 mji 0,1 μοληρηογο kmhh φοοφ3ΤΗθΓθ δγφερθ c pH=8,5 6bUio CMemeHO c 1,1 3μγ 6HOTHHHJi-8-aMHHOKanpaHOBoft KHCJioTbi-N-niiipoKCHcyuMHHMHna (φπρΜΜ “BēpHHrep MaHHxaftM Γμ6Χ”), pacTBopeHHoro b 50 m/i flHMeTHJicyj^0KCHna (MOJiapHoe cooTHouieHHe HMMyHorjio6yjiHHa IgG κ 6ηοτηηυ=1 :7,5) m nocjie nepeMeuiHBaHHB HHKy6HpoBaHO b TeneHHe 90 mhh πρκ TeMnepaType 25°C. EHOTHHHJIHpOBaHHblft HMMyHOrJIo6yJIHH IgG 6bUl ZlHaJIH3HpOBaH B TeqeHHe hohh npn TeMnepaType 4°C OTHOcHTejibHo 2 MMOJiapHoro κ3ΛΗήφοοφ3ΤΗθΓθ 6yφepa c pH=7,0 ββιχολ: 45 MAK33-IgG-6noTHHa b 6,4 mji.
b) “CuiHBaHHe” co cipenTaBimHHOM 4 mji pacTBopa MAK33-IgG-6HOTHHa c npoMexcyTKaMH 5 mhh CMeiHHBaJIHCb C 3 HaCTHMH ΠΟ 1,5 ΜΓ CTpenTaBHŪHHa (φΗρΜΗ “BēpHHrep MaHHxaftM Γμ6Χ”) b 50 mmojihphom καπΗίιφοςφΒΤΗΟΜ 6yφepe/0,l MOJIflpHblft XJIOpHJI ΗΒΤρΗΗ H HHKy6HpOBajIHCb B ΤβΗβΗΗβ 20 MHH ΠρΗ TeMnepaiype 25°C. MojiHpHoe OTHomeHHe HMMyHonio6yjiHHa 1 C κ 22 CTperrraBHZtfiHy=2,5:l. Hcxo^Haa CMecb 6buia KOHueHTpupoBaHa c noMoinbio νΛΒτρΒφιυΐΒτρ3ΐ1ΗΗ no 2 mji η, KaK b npHMepe 1, Χρ0Μ3Τ0Γρ3φΗρ0ΒΒΗ3 Ha KOJIOHKe AcA22. Bce φρ3ΚΙ1ΗΗ C MOJieKyjIHpHbIM BecoM 6o;iee 320000 6bum oOte^HHeHbi.
Bbixon: 21 μγ arperaTa MAK33-IgG-CTpenTaBiWHHa b 12 mh pacTBopa c 17 μγ coaepncaHHn HMMyHonio6yjiHHa IgG. IIpHMep 7 “CuiHBaHHe” MOHOKJiotiajībHoro aHTHTejia aHTHajībSvMHHa genoBeKa c ajībOvMHHOM gejiOBena 40 μγ ajib6yMHHa nenoBeKa (φκρΜΜ “EēpHHrBepKe”, Map6ypr) 6bUio arperapoBaHo b Imji 50 MMOJiapHoro κ3ΛΗίίφοοφΒΤΗθΓθ 6yφepa c pH=7,0 nyTeM HarpeBaHH^ b TeneHHe 3 nacoB no 70°C. Ilocjie oxjia*aeHHH no 25°C HacTb c 25 μγ arperaTa ajib6yMHHa nenoBeKa 6buia pa36aBJieHa 50 MMOJIHpHbIM Κ3ΛΜίίφθθφ3ΤΗΗΜ 6yφepOM, COnepnCaLUHM 0,1 ΜΟηίφΗΜΗ NaCl, c pH 7,0 no KOHueHTpanHH 2,5 μγ/mji h nepe3 npoMe*yrKH b 5 mhh npHBeniHBajmcb 4 MacTM no 2,5 μγ MAK MI-aHTHajib6yMHHa HejioeeKa (raMMa 1, Kanna), pacTBopeHHoro b 0,2 Mn 50 MMonnpHoro ΚΒΠΗίίφοοφΒΤΗΟΓΟ 6yφepa c pH 7,0. Ποαιε 20 mhh HHKy6auHH npH TeMnepaType 25°C CMecb 6bnia KOHueHTpwpoBaHa c noMombio yJIbτpaφHJIbτpa^HH ao 2 mji h xpoMaτoΓpaφHpoBaHa, KaK h Bbirne, Ha rejieBoft Ko/ioHKe AcA. Conepacainne προτεΗΗ φρηκιΐΗΗ c MoneKyjwpHbiM BecoM 6ojiee 320000 Gburn o6bennHeHbi.
Bbixon: 12,4 μγ arperaTa MAK MIIgG -ajib6yMHHa b 7,8 mji c conepacaHMeM 8,86 μγ HMMyHorno6y;iHHa IgG. LV 10538 IļpHMep 8
CpaaHeHHe vcToaHeHHH MemaiomHx cbaKTOPOB ηητηβηογο MAK33-IgG h pa3JiHHHbix arperaTOB MAK33-IgG b CEA 3H3HM-HMMyHonpo6e c jlbvmh cneuH0ngecKHMH peaicraHTaMH MOHomioHajībHbK aHTHTeji
BbuiH Hcnojib30BaHbi peaKTHBbi H3 TecT-ynaKOBKH 3H3hmhh R CEA (<|>HpMa “BepHHrep MaHHxaHM Γμ6Χ”). CoaepacaBiuiiecH b stom τεοτε προδκρκΗ 6buiH noKpbrrbi MOHOKJioHajībHbiM ΟΕΑ-επείίΗφΗΗεεκΗΜ MHIUHHblM HMMyH0rJI06yjIHH0M (IgG I, K). 3H3HMMapKHpOBaHHblft p8aicraHT «ΒΛΛετε» MOHOKJlOHajībHbiM, ΟΕΑ-επεαΗφΗπεεκΜΜ KOHbioraTOM MbiiiiHHOH Fab-n8poKcuaa3bi; no^iaiaccoBbiM cocTaBOM Fab HBJIH8TCH K, γ I).
Pa3JiHHHbi8 np8napaTbi MAK33-IgG ^oāaBJiajiHCb bo Bce B03pacTaiomeft KOHueHTpauHH εοοτΒετετΒεΗΗο k HHKy6au;HOHHOMy 6γφεργ H HCIlbITaHH8 npOBO^HJIOCb C CbIBOpOTKOH HejIOBdCa (P43), B κοτοροή 6biJiH o6Hapy*8Hbi HeoSbmaftHo 3φφεκτΗΒΗΗε HapymaioiuHe φΒκτορΜ. Ta6jiHiia 1 rioKa3biBaeT KomiempaiiHio ripenapaTa MAK33-IgG (b μκγ npoT8HHa/mji) b HHKy6auHOHHOM 6γφερε, KOTopaa noaaBjiHjia Hapyui8HH8 HacTOJibKo, hto 6buio o6HapyaceHO npaBmībHoe co,nep:>KaHne aHajiHTa b HopManbHOM /īHana30He (1-3,5 ht/mjī). 24
Ta6jiuua 1 OTHOCHTejibHaa Φυηκβηη ycTpaHeHH« BpeoHbix φακτοροβ pa3JiHHHbix
npenapaTOB MAK33-IgG J(o6aBKa κ HHKy6aiiHOHHOMy βγφερ^^ mkt/mji OaKTOp ycTpaHeHHa HapjmeHHH 3kcthhkiuvi Kaagmeeca coaepacaHH e CEA b cuBopoTKe P43 ηγ/μ.ι Eē3 ao6aBKH 0 . 1,636 >58x> MAK33-IgG MOHOMepHbiii 9600 0,0026 0,132 3,4 MAK33-IgG -arperaT/GDA (HcxoaHaa CMecb 1) 34 0,74 0,126 3,1 MAK33-IgG -arperaT (HcxoaHaa CMecb 2c) 25 1 0,125 3,1 MAK33-IgG -aeKCTpaH (3) 43 0,58 0,129 3,3 ArperaT HMMyHonio6y.JiHHa KpynHoro poraToro CKOTa MAK33-IgG (4) 82 0,3 0,130 3,3 ArperaT MAK33-IgG-Fab (5) 3 8,33 0,122 2,9 X)
BejiHHHHa JiexnT BHe 30Hbi Κ3λη6ροβοηηοη κρΗΒΟΗ, onpe^ejieHHoii τοπκοή Kajin6poBKH. ΠρκΜβρ 9
VcTPaiMiomee HapvmeHm iieftcTBHe arneraTOB MAK33-īeG. κοτοΡΜβ 6mjih “cilIHTbl” C nOMOmblO HeKOBaJieHTHhK 6Η0ΒΦΦηΗΗΜΧ CBfl3ēH. b CEA 3H3HMHH -TēCTe
PeaKTHBbi h npoBeaeHHe ηοπμτβηηλ cmotph b npHMepe 8.
OaKTHnecKoe co^epxaHHe KapuHH03M6pHOHajibHoro aHTHreHa (CEA) Hcnojib30BaHHoft npoēbi cbiBopoTKH HejioBeKa, onpe^ejieHHoe c noMombio 6a30Boro MeTO.ua, cocraBM/io 2,8-4,2 ηγ/mji. Ta6jiHua 2 noKa3biBaeT cnHTaHHbie Ha 3TajioHHoft kpmboh Ka«ymweca KOHueHTpaiļHM CEA ņjih npo6bi cbiBopoTKH HejioBeKa (JN2IO8), KOTopaa LV 10538 coaep>KHT HapyuiaiOLiiHe φ3κτορω, πρκ pa3JiH4Hbix ao6aBKax arperaTa HMMyHorjio6yjiHHa κ HHKy6aii;HOHHOMy 6yφepy.
TaSjiHna 2 ycTPaHflioiiiHe HapvmeHHa arperaTbi HMMVHorjio6vjiHHa IgG c ΟηοβΦΦηηημμ
06pa30BaHHeM MOCTHKOBbtX CB«3eH ĶoftaBKa κ HHKy6aimoHHOMy βγφβργ ΜΚΓ IgG/MJI CbiBopoTKa 4ejioeeKa JV° 108 ηγ CEA/mji Be3 Ao6aBKH - 40 MoHOMepHbm MAK33-IgG 200 33,4 500 31,4 MAK33-IgG CTpenTaBKOHH I 28,5 ArperaT H3 npnMepa 6 10 8,8 MAK MI-IgG-ajib6yMHH 2,5 36,7 HejioBena ArperaT H3 npnMepa 7 7,5 25,1 H3 Ta6jiHm>i βηληο, ητο 6μοβΦΦηηηο-οβ5Ι33ΗΗΙ>ι6 arperaTbi HMMyHorjio6yjiHHa IgG, OTHeceHHbie κ BecoBOMy KOJiHHecTBy MMMyHOrJIo6yjIMHa IgG, 3Ha4HTeJIbH0 3φφβΚΤΗΒΗβ6 yCTpaHHIOT BpeflHbie φ3κτορΗ, 4eM HecBH3aHHbift HMMyHorjio6yjiHH IgG: κο3φφΗΐιεΗΤ 6ojiee 500 hjih 6ojiee 60. Hcno;ib3yeMoe KOJiHHecTBO 6buio BbiOpaHo TaKHM o6pa30M, ητο nojiyMHJiocb TOJibKO HacTHHHoe ycTpaHeHHe BpeaHbix φΒΚΤΟρΟΒ; HMeHHO npH ΤΒΚΗΧ yCJIOBHHX HaHJiyHUIHM o6pa30M oiieHHBaeTca OTHOcmejibHoe ycTpaHHK>mee HapyuieHHe ji?hctbhh pa3JiH4Hbix npenapaTOB. 26 IļpHMep 10 3aBHCHMOCTb vcTpaH5nomeH HapvmeHHa Φυηκιιηη οτ MOJieKVjiHPHoro Beca
arperaTa MAK33-IgG
PeaKTMBbi h cnoco6 npoBeaeHHH 3τογο onbrra TaKHe xe, KaK h b npHMepe 8. ūpenapaTbi MAK33-IgG nojryHeHbi b cootb6tctbhh c npHMepoM 2.
Ta6jnnia 3 ycTpaHSHomee HaovmeHHa βθηοτβηθ arperaTOB MAK33-IgG b 3aBncnMOCTn οτ MOJieKVJiapHoro Beca 4o6aeKa κ HHKy6aimoHHOMy βγφεργ CbiBopoTica naimeHTOB N° 181* CbiBopoTKa naimeHTOB JV° 431) 3kcthhum« ΗΓ CEA/mji2) 3kcthhiubi ΗΓ CEA/mji2) Be3 ao6aBKH 125 mkt/mji ΜΟΗΟΜβρΗΟΓΟ 1,567 m 00 1,636 583> MAK33-IgG 0,148 3,9 1,703 58 10 mkt/mji arperaTa MAK33-IgG, HCX0AHaa cMecb 0,115 2,7 0,179 6,2 30 mkt/mji arperaTa MAK33-IgG, HcxoaHaa CMecb 0,125 3,1 5 mkt/mji arperaTa MAK33-IgG, MOJieK>jmpHbiH eec 2-10 MJIH. 0,105 2,1 0,137 3,9 5 mkt/mji arperaTa MAK33-IgG, MOJieKyjiapHbiH eec 1-2 MJIH. 0,109 2,4 0,285 11,0 5 mkt/mji arperaTa MAK33-IgG, MOJieKyjiapHbiH eec 400000-1 mjih. 0,155 4,8 0,051 53,7 5 mkt/mji arperaTa MAK33-IgG, MOJieKyjiapHbiH eec 160000-400000-1 mjih. 0,364 16,3 1,239 58 LV 10538 1) OnpeaejieHHoe c noMombio 6a30Boro Mera^a aeficTBHTejibHoe co^epiKaHHe b CEA Haxo^HTCfl b ,aHana30He 1-3,5 ηγ/mji. 2) KaxymeecH coaepHcaHHe CEA onpe^ejiacTCfl no 3κοτηηι1ηη h 3Ta^OHHOft KpMBOH C nOMOlUbK) CTaHHapTHbIX npo6 CEA b cooTBeTCTBHH c HHCTpyKiineH no pa5oie &/ih 3H3HMyHa CEA. 3) KpoMe onpe^e^eHHoro c noMombio STajiOHHoft toniku yqacTKa STaJIOHHOH KpHBOH. IIpHMeD 11
CpaBH6HH6 vcTPamnomero HapvmeHHfl aetiCTBHa aroeraTOB MAK33-IgG. nOJTVMeHHbCC H3 pa3J!HMHbIX MOHOKJIOHaJIhHbK aHTHT6JI
EbUIH HCn0JIb30BaHbI npo6MpKM H3 ynaKOBKH 3H3HMHH R TSH(<ļ)HpMa “EēpHHrep MaHHxaiiM Γμ6Χ”), κοτορωβ ποκρΗΤΗ MOHOKJIOHajIbHblM ΕΗΤΗ ΤΗρβΟΤρΟΠΗΗΟΜ ΜΜΙΙΙΗΗΟΓΟ HMMyHODI06yjIHHa (IgG I, K). OcTajībHbie peareHTbi, KaK h b npHMepe 8, 6biJiw 3aHMCTBOBaHbI H3 3H3HMHH CEA-ynaKOBKH. HcnblTaHHe npOBO^HJIOCb B COOTBeTCTBHH C HHCTpyKIJH6H ΠΟ pa60Te C 3TOH ynaKOBKOH. Πρκ 3TOM npoBeneHHH HcnbuaHMa He MoaceT 6biTb no^aH ημκβκοη cHraaji c noMombio coaepacamūi aHajiHTa npo6bi cbiBOpoTKH, ποτομυ, hto o6a cneup^ireecKitt peaKTaHTa hmciot pa3JiHHHyio οπ«ΐΗφΗΗΗοσπ>. TaKHM o6pa30M pe% ΗΛβτ tojibko o MoaejiH TecTa, KOTOpbift c noMontbio npo6bi CbiBopoTKH BbmaeT TOJibKO Toraa οηγηοιι no BejiHMHHe rameHHH, Koraa npoHBJiHioTca BpeaHbie φ3κτορΗ. ripHBJieqeHHbie min cpaBHeHHH arperaTbi MOHOKJioHajībHoro ammejia HMMyHorjio6yjiHHa ΜΑΚ-IgG 6buiH nojiyyeHbi no aHanornH c npHMepoM 2c ii3 MAK33. 28
Ta6jimia 4
CpaBHeHHe arperaTOB HMMVHorjio6vjiHHa IeG pa3JiHHHbix MQHoimoHajibHMx aHTHTeji no vcTpaHaioineMV HapvmeHHa jeHCTBHio b TecT-MoaejiH
Ao6aBKH κ HHKy6am<OHHOMy δγφεργ mkt/mji 3kcthhuhh b cbiBopoTKe P43 ArperaT MAK33-IgG (2c) 0 0,900 HCX0AHaa CMecb 1,25 0,506 2,5 0,366 5 0,238 10 0,195 20 0,152 ArperaT MAK M S43-IgG 0 0,900 HCX0AHaa CMecb 1,25 0,554 2,5 0,506 5 0,406 10 0,202 20 0,180 3kcthhuhh zuih npo6bi cbiBopoTKH 6e3 CEA h 6e3 HapymaioinHX «ļmKTopoB: 0,162.
Pe3yjibTaT: ycTpaHHK>mee HapyuieHHH fleficTBiie pa3JiH4Hbix MOHOKJioHajibHbix arperaTOB MAK-IgG o/umaKOBo b paMKax rpaHHU οπίΗδοκ. LV 10538 IIpHMep 12
YcTPaH5nomee HapvmeHHH jeftcTBHe arperaTa MAK33-IgG h MOHOMepHoro HMMVHOrJIoSvJIHHa MAK33-IgG B TeCTe C SūOTHHHJIHpOBaHHhlMH DeaKTaHTaMH MAK-IgG B 3tom TecTe Hcnojib3yeTc» ziBa MOHOKJioHajibHbix renTaraTO-ΠΟΒερΧΗΟΟΤΗΗΧ (HB Α)-0ΠεΐίΗφΜΗ60ΚΗΧ HMMyHorjio6y^HHa MOHOKJioHajibHMx aHTHTeji MAK-I C b ČHOTHHHJiHpoBaHHofi φορΜε (6H0THHHJiHp0BaHHH8 npoBeiīeHO b cooTBeTCTBHH c: T.V. Updyke G.L.Nilson in methods in Encymology, 121 (1986) 717-725). Οληη H3 hhx, MAK6E7-IgG ΗΒΛίίετοκ πολτηπομ IgG I/K, apyroft, MAK5A10-IgG, «BJIH8TCH ΠΟΛΤΗΠΟΜ I C2a, K. B KaneCTBe 3Η3ΗΜ3ρΚΙφΟΒ3ΗΗΟΓΟ peaicraHTa 6bui Hcnojib30BaH MAK5A10-Fab -POD-KOHbioraT.
Cocrae HHKy6aiiHOHHoro δγφερβ: 40 MMOJiefi φοεφΒΤΗΟΓο 6yφepa c βολοροαημμ noKa3aTe/ieM 7,0 0,2 MOJIHpHblH epeilHHii BHHHOKHCJIblil HaTpttft 0,5% (W/V) ajib6yMHHa chbopotkh KpynHoro poraToro CKOTa 0,1% (W/V) HMMyHonio6y;iHHa IgG KpynHoro poraToro CKOTa 0,5% (W/V) njiypoHHKa F 68 0,01 (W/V) φεΗο^ 200 ηγ/mji MAK6E7-IgG (6ηοτηηηλμροβ3η) 25 ηγ/mji MAK5A10-IgG (6noTHHHjmpoBaH) 200 mu/MJi MAK5A10-Fab -POD-KOHbioraT HcxojiHbie CMecH arperaia MAK33-IgG 6buin nojiyHeHbi b cooTBeTCTBHH c npHMepoM 2c. TIjih TecTa πηπετκοίί 6buio BBeneHO no 0,2 mji npo6bi chbopotkm h 1 mji HHKy6auHOHHoro 6yφepa b npo6npKy H3 nojincrapojia, KOTopaa 6buia noKpbua cTpenTaBHAHHOM. 3aieM cMecb HHKy6HpoBajiacb b τεπεΗΗε 4 4acoB npH KOMHaTHoft TeMnepaType. 3aTeM Kaxcaaa npo6HpKa 6biJia 30 npoMbiTa 3 χ 1,5 mji βολοπροβοληοη bo^h h 6mjio ,ao6aBJieHo no 1 μλ pacTBopa cy6cTpaTa (ABTS/nepoKcna) H3 3H3hmyh CEA-TecTOBoft ynaKOBKM. riocjie HHKy6auHH b TeHeHHe naca πρη κομη3τηοη TeMnepaType 6buia H3MepeHa skcthhuhh b npeo6pa30BaHHOM pacTBope cy6cTpaia npn 405 hm.
Ta6jnma 5
CpaBHeHHC vcTpaHaiomero HapvmeHim aeftcTBiia npenapaTOB MAK33-IgG b JBVXCJ1QHH0M 3H3HMHMMVHOTeCTe C 6nOTHHHJlHpOBaHHbIMH MAK33-IgG
peaKTaHTaMH JļoēaBKa κ HHKy6aimoHHOMy 6y<l>ePy mkt/mji 3kcthhkuhh AFia npo6bi CbIBOpOTKH Na 1001 No 4891 2 Ee3 .aoOaBKH 0 1,390 0,262 0,042 MoHOMepHbiH MAK33-IgG 1 - - 0,042 5 1,070 0,102 0,045 10 0,884 0,068 0,048 200 0,125 0,042 0,046 400 0,080 0,048 0,049 ArperaT MAK33-IgG (2c) 0 1,044 0,378 0,047 HCXOAHaa CMecb 1 0,125 0,034 0,043 5 0,043 0,045 0,048 10 0,048 0,035 0,054 I: FIpo6bi CbiBopoTKH 100 h 489 6bum nojiyHeHbi H3 xpaHHJwma flOHOpCKOH ΚρΟΒΗ H 6bIJIH CBOGO^HO fleKJiapHpOBaHbl KaK HBSAg. 2. ripoāa 3/ļopoBoro .aoHopa, KOTopan He co/iep*;HT hh HBSAg Hapyuiaemero (ļ>aicropa. LV 10538 Μ 3 flaHHbix, hto ftiifl cbiBopoTKH N° 100 flocTHraeTCH to ace caMoe ycTpaHeHMe HapymeHMft no cnrHa^y 0,125 c noMombio 200 μκγ/μλ MOHOMepHoro MAK33-IgG μλη I μκγ/μλ arperaTa MAK33-IgG, cjie,nyeT, hto λπη 3Toro TecTa arperaT HMMyHorjio6yjiHHa IgG b 200 pa3 aKTHBHee c tohkm 3peHHH ycTpaHeHHH HapymeHHH. ΠΡΗΜβΡ 13 ycTPaHgiofflee HāPvmeHHa neHCTime arperaTa MAK33-IgG b Tecre c cvxhmh XHMHHeCKHMH HOCHTCJIHMH ρβΕΚΤΗΒΟΒ
OnpeaejieHHe npoBoaHTca c noMombio cyxnx xnMHHecKMx HOCHTeJien peaKTHBOB B O^HOCTaiiHHHOM TeCTe B COOTBeTCTBHH c ΠρΗΗΙΙΗΠΟΜ CJIOHCTOH TBep^OH φΒ3Μ ΛΒΟϋΗΟΓΟ aHTMTeJia B ρΟΤΟρΗΗΧ BCTaBHbix 3JieMeHTax c ueHTpo6excHbiM aHajiH3aTopoM c noMombio onHcaHHOH b BbuioxeHHoft 3aaBice ΦΡΓ N° 34250085 aHajiH3HpyiomeH annapaTypbi.
1. riojiyHeHHe pacTBopoe peaKTHBOB a) 6yφep 1 50 MMOJieft/Λ κ3ΛΗήφοοφ3ΤΗθτο 6yφepa, pH=6,0, nojiyqaeTCH nyreM cMemHBaHHa 50 MMOJieft/ji pacTBopa K2HPO4 n 50 MMOJieii pacTBopa KH2PO4 λο ΛοοτΗΧβΗΗίΐ pH=6,0.
b) 6yφep II
Byφep II nojiyHaiOT tohho Tarace, KaK h 6yφep I, c τοίί Jiniub pa3HHueH, hto ycTaHaBJiHBaeTCH pH=7,5 h hto 6yφep flonojiHHTejibHO coaepxHT 10 γ/ji ajib6yMHHa cmbopotkh KpynHoro poraToro cmra h 150 MMOJieft/Ji NaCl. 32 c) PacTBop peaKTaHTa Rj, cnoco6Horo coeaHHiiTbCH c THpeOTpOnHHOM (T H). B KanecTBe peaicraHTa Rļ, Hcnojib3yeTca MOHOKJioHajībHoe MbiniHHoe aHTHTejio THpeoTponHHa. Co/iepacamafl sto aHTHTejio aClļHTHHeCKa« ļfcHUKOCTb ZloāaBJIHeTCH ΛΟ 1,8 MOJIH CyJϊbφaTOM aMMOHHH. OcaaoK pacTBopaeTca b 6yφepe H3 15 MMOjien φοοφ3Τ3 Harpna c pH=7,0 h 50 MMOJiefi xjiopHfla HaTpHfl. nojiyHeHHbiH tbkhm o6pa30M pacTBop no^BepraeTCfl naccaxcy c noMombio DEAE-nejunojio3hi. riojiyqeHHoe TaKMM o6pa30M aHTHTejio, cnocoSHoe coe^HH«Tbca c τκρεοτροπΗΗΟΜ (TSH) 6HOTMHHJiHpyeTC5i (5 6HOTHH/IgG) h pa36aBJiiieTCH 6yφepoM II no KOHiļeHTpaiļHH npoTeHHa I mt/mji. b) 3H3HMMapKHpoBaHHbift pacTBop peaicraHTa R2. B KanecTBe peaicraHTa R2 Tarace Hcnojib3yeTca MOHOKjioHajībHoe MbiuiHHoe aHTHTejio THpeoTponHHa, κοτοροε, ojiHaKo, pacno3HaeT HHyio aHTHreHHyio jieTepMHHaHTy, MeM peaicraHTa Rļ,. Cojiep^camaa sto aHTHTejio aciiHTHHecKaH acmiKocTb onHinaeTCfl, KaK yKa3aHo b nyHKTe 1.3. IlojiHoe aHTHTejio pacmenjuieTCH H3BecTHbiM o6pa30M b cootbctctbhh c mctouom P.P. IIoTepa, EHoxHMHHecKHft xcypHaji Ne 73, (1959), crp. 119, Ha Fab- φρΒΓΜβΗΤ. riOJiyMeHHbie Fab-φpaΓMeHTbI B COOTBeTCTBHH C ΜβΤΟΛΟΜ, onHcaHHbiM b HCTOHHHKe: Ischikava et al, J. of Immunologssay 4 (1983), οτρ. 209-327, cocjihhhiotch c -raji0KT03Hfla30H. PacTBop peaicraHTa R2, pa36aBjineTCH b 6yφepe II no KOHneHTpaiļHH 500 mu/Mji (copa3MepHO c ο-ΗΗτροφβΗΗ.ίΐ-β-Γα;ιοκτο3ΗΑ33θΗ πρπ TeMnepaType 37°C). e) ycTpaHfliomHfi HapyuieHHH προτβΗΗ MAK33-IgG-nojiHMep, nojiyHeHHbiH no aHajiorHH c npHMepoM 2, pacTBopaeTca b 6yφepe II λο KOHneHTpanHH I μγ/mji. LV 10538 f) PacTBop aBHflHHa Αβηλμη pa36aBJiHeTCH b βγφερε I ķo KOHueHTpauHH npoTeHHa 50 mkt/mji. g) PacTBop cy6cTpaTa KpacHbitt ΜορφβΗΟΛ-β - rajiaKT03na (nojiyHeHHbiH 5 mmojich/ji B COOTBCTCBHH C ΒΜϋΟΧβΗΗΟΗ 3ΒΒΒΚΟΗ ΦΡΓ JV° (3,05 γ/ji 3345748) HEPES 70 MMOJieū/a (16,7 γ/ji NaCl 154 mmojib/ji (9 γ/ji) AjIb6yMHH CbIBOpOTKH KpjTIHOrO poraTOrO CKOTa 0,3% (3 γ/ji) Tbhh 20 0,2% (2 γ/ji) pH (c NaOH) 7,25
2. IIojiyHeHHe Hoarrejiefi peaKTHBOB a) HocHTejib peaKTHBOB 1 (6e3 ycTpaH«jomero HapyuieHHa npoTeHHa) 40 mkji pacTBopa, κοτορΗή Ha Kaagibift jihtp cojiepxMT 100 MMOJieii <ļ)oc<J)aTa HaTpRa pH 7,3 (37°C), 2 mmojih xjiopnaa MarHHfl, 9 r xnopnqa HaTpHa, 5 r ajib6yMHHa cbraopoTKH KpynHoro poraToro cKOTa, 0,5 ΜΓ 6HOTHHHJIHpOBaHHOrO aHTHTHpeOTpOlIHHHOrO MOHOKJIOHaJIbHOrO aHTHTejia mmihh (peaicraHT Rj)ļ 1000 ejtHHHp μηπιηηογο aHTHTHpeoTpon ηηηογο aHTHTejia Fab^parMeHTa-P-raJiaKT03iwa3bi (pacTBop peaicraHTa R2) (aKTHBHOCTb onpe^ejiaeTCH c noMombio ορτο-ΗΗΤρθφ6Ηνυΐ-β-0-Γ3Λ3ΚΤ03Η,Ζϊ3 IIpH TeMnepaType 37°C), HaHOCHTCH KaruiHMH Ha bojiokhhct)to Maccy, cocTO«myio H3 KOMMep^ecKoii πο;ΐΗ3φΗρΗθίί 6yMara. 3aTeM npoH3BojiHTCii cyniKa npH κομηβτηοη TeMnepaType. 3th BOjiOKHHCTbie MaTbi xpaHHTca λο hx npuMeHeHna npw TeMnepaType 4°C η othochtcjibHoh BJiaacHOCTH 20%. 34 b) HocHTejib peaKTHBOB Γ (c ycTpaHHiomHM HapymeHHH npOTeHHOM) ΠοπγπεΗΗε ocymecTBJiHeTCH Taoce, KaK h HocMTejia peaKTHBOB 1, c Toii JiMiub pa3HHueft, hto jonojiHHTejibHo Ha Ka*abift jihtp προπΜτοΊΗΟΓο pacTBopa co^epxHTca 0,01 r arperaia MAK33-IgG H3 npHMepa 2c (Hcxo<n;Haa cMecb). c) HocHTejib peaKTHBOB 2
Ha itejuiiojio3HOM bojiokhhctom MaTe β cooTBeT ctbhh c OpoMiiHaHOBbiM cnocoOoM aKTHBH3auHH (BbUioHceHHaa 3aaBKa ΦΡΓ N° 1768512) φΗΚοπργετοΗ aBna,HH (pacTBop aBHaHHa) npHHeM Ha Ka^Kabift rpaMM BOJiOKHHCToro MaTepHana jum φκκοΗροΒ3ΗΗΗ npe&aaraeTca 10 mkt aBHaHHa. ΠγτβΜ προμμβκη yaajifleTca HecoeanHHBiiiHece aHTHTejio h BOJIOKHHCTblH MaT OCTOpOJKHO BbICyiHHBaeTCH npH KOMHaTHOH TeMnepaType. XpaHeHHe no;iyHeHHbix tbkhm o6pa30M βολοκηηοτμχ MaTOB ocymecTB^aeTCH no aHanornH c xpaHeHHeM HocHTejui peaKTHBOB 1.
3. ΠροββΑβΗΗβ onpeAejieHHB
Onpe,aejieHHe c noMombio 3thx o6ohx HOCHTejieft peaKTHBOB 1 h 2 hjih Γ h 2 ocymecTB^^eTca c πομοιηβιο onHcaHHoro b BbuioaceHHoft 3MBKe ΦΡΓ Ne 3425008. 5 ycTpoiicTBa /uih npoBeaeHHB aHa;iHTH4ecKHx onpejiejieHHH. 3to ycTpoHCTBO co^epxcHT BCTaBHOH 3JieMeHT poTopa jum HeHTpo6eXCHbIX aHaJIH3HpyiOmHX aBTOMBTOB, COCTOHlIļHH H3 φΒΟΟΗΗΟΓΟ Kopnyca, KOTopbiii HMeeT KaMepy juia HaHeceHHH npo6bi, KOTopaa coe^HHeHa c ēojibiuHM KOJiHMecTBOM nojien peaKTHBOB, κοτορκε cooTBeTCTBeHHo co^ep)KaT nponHTaHHbiii onpeaeaeHHbiM peaKTHBOM rHipocKonHnecKHH MaTepnaji-HocHTejib, h HMeeT no MeHbiueft Mepe oflHy LV 10538 CMecHTejn>Hyio KJianaHHyK) KaMepy h onHy H3MepMTejibHyio xaMepy, KOTopbie coBMecTHO o6pa3yioT nyrb TpaHcnopTMpoBKH Hcc;ie,ayeMOH jkmukocth, κοτορΗΗ Be,geT pa^HajībHo H3HyrpH paUHajībHO Hapyacy, ecjiH BCTaBHoft 3JieMeHT 3aKpeiuieH Ha ροτορε, η κροΜβ τογο BeaeT no MeHbineH Mepe b Blpyryio xaMepy mm npoBejieHHa H3MepeHHfl h no MeHbmeii Mepe HacTHHHO naeHTH4eH c nyreM TpaHcnopTMpoBKH Hcc/iezīyeMOH jkhzīkocth. ΠρΗ 3tom nyTb jum TpaHcnopTMpoBKH HCCJieayeMoft «mukocth BeiieT ot KaMepbi λπη 3arpy3KM προ6ω (P) nepe3 3anojiHeHHyio ΓΗΓροοκοπΗΗΗΗΜ MaTepnajiOM KaMepy (a), conepacaiu;yio 6yφφep, Mepe3 KaMepy (D h pacnojioxeHHyio Mexay KaMepaMH (a) h (c) nepBjro KjianaHHyio KaMepy (VKI) ko BTopoft KianaHHOH KaMepe (VK2) m ot Hee nepe3 xaMepy (D) h npHeMHyio Ka.Mepy (AK) κ H3MepHTejn>HOM KaMepe (K). iļjiH 3arpy3KH apyroft jkhukocth npejrycMOTpeHa BbinojiHeHHaa b BKae HacocHOH KaMepbi cy6cTpaTHaa KaMepa (PK), KOTopaa nepe3 ao3Hpyiomyio KaMepy (DK) h cocToamee H3 KanHJurapoB (Kap) ao3npyiowee ycTpofrcTBo h nepenycKHyio KaMepy (ŪK) coe^HHeHa co Βτοροή KaMepoft (VK2) (cmotph Φηγ.2). Jļjm onpeaejieHHH skcthhlihh “a” (H3MepMTejibHbin cnmaji, Bomaa CHrHaii noMexn) HcnoJib3yiOTCH HocHTejib peaKTHBOB 1 h HocHTejib peaKTHBOB 2, mm onpeaejieHm skcthhkūhh “b” (οπείίΗφΗΗεοκΗϋ H3MepeHHbiž cHTHaji 6e3 cnma^a noMexH) Hcno^b3yK>Tca HocHTejiH peaKTHBOB Γ h 2.
HocHTejib peaKTHBOB I hjih Γ pa3MemaeTCH Ha nojie “c” BcraBHoro ajieMenra poTopa h HocHTejib peaKTHBOB 2-Ha no;ie “d”. Πρκ 3tom 40 mkji KOHneHTpHpoBaHHOH npo5bi BBOflHTCH HenOCpeflCTBeHHO ΠΗΠεΤΚΟή nepe3 oTBepcTHe Ha ΒβρχΗβίί KpoMKe Ha noji ”a”. 270 mkji pacTBopa cy6cTpaTa bbo^htch b KaMepy PK. C noMombio HaAJieacameH nporpaMMbi ΗβΗτρκφ^ΗροΒΒΗΗΗ, b κοτοροΗ BbicoKaH nacTOTa BpameHHH *iepejiyeTCfl c ocTaHOBKofī, npo6a h pacTBop cy6cTpaTa TpaHcnopTHpyeTca 3aieM b HanpaBJieHHH pa3jjejiHTejibHoft Maipimbi h KiOBeiTbi. 36 Πρκ 3ΤΟΜ β npouecce OTpa6oTKH nporpaMMbi peaicraHTbi Rj h R2 6e3 ycTpaHHK>mero HapyuieHHH npoTeHHa hjih c hhm BbiMbiBaioTCH McnbīTbiBaeMOM jKHflKOCTbK) c πόλη “c” m 3aTeM roMoreHHaa CMecb no^aeTca λλη npoBe^eHHH peaKUMH. Ha nojie “d” o6pa30BaHHbie KOMiuieKCbi coe^HHHiOTca c noMombio peaKTaHTa Rļ c ηβηλ,ηηομ. IlepeHOC npo6bi c πόλη “c” Ha none “d” ocymecTBHHeTCH b TeneHHe OHeHb ΚΟρΟΤΚΟΓΟ ΒρβΜβΗΗ.
PacTBop cy6cTpaTa c noMoujbio fl03Hpyiomeft KaMepbi K pa3/ieHHeTCH Ha πορππΗ, H3 κοτορΜΧ nepBan npe^Ha3HaHeHa juih BblMblBaHHH Η36ΗΤΟΗΗΟΓΟ ΗβΚΟΜΠΛβΚΟΗρΟΒΒΗΗΟΓΟ KOHbloraTa.
HapyiiiaK>mHe φακτορπ, KOTOpbie μογλη 6bi cBH3biBaTb peaKTaHT R2, HeftipaHH3yeTCH πρκ ηοπολβ3οβ3ηηη 10 μγ ycTpaHHiomero HapyuieHHH npoTenHa/ΜΛ HccHenyeMoro pacTBOpa h Tarace BbiMbiBaiOTCH (HCn0Hb30BaHHbie HOCHTeHH peaKTHBOB Γ). CBH3aHHaH nepe3 o6pa30BaHne KOMruieKca Ha none “d” aKTHBHOCTb P-raH0KT03Haaa3bi nponopnHOHanbHa co^ep>KameMycH b npo6e KOHHHecTBy THpeoTponHHa ηλη xonocTOMy 3Ha4eHHio npoGbi. 3īa aKTHBHOCTb onpeaeHHeTCH c noMombio λρυγοη πορπηη cy6cipaTa, npHHeM cy6cTpaT b xoae 5-μηη>τήοη peaKUHH npeo6pa3yeTCH b UBeTHbie npoayKTbi. 06pa3OBaBiiiHecH neeTa h flanbHeHuiee UBeToo6pa30BaHMe/μλ Β ΧΗΛΚΟΗ (ļ)a3e H3MepHK)TCH B KIOBeTTe πρπ 576 HM. Πρκ 3thx υολοβηηχ 6buiH nonyHeHbi cHeAyioinHe pe3ynbTaTbi. LV 10538
TaOjiHua 6 IIpo6a a 3kcthhiqui (ea. Maccu) Komieinpa mm (μκθλ/μλ) 3kcthhumh (ea. Maccu) KoHueinpa IUU (μκθλ/μλ) TιιρβοτροπΗΗ KajIn6paTOp 0 MKefl/wJic^ 451 0 457 0 TΗρβοτροπΗΗ Ksuni6paTop 19,6 mk ea/»u1 2 3331 19,6 3311 19,5 CbiBopoTKa HejioeeKa 1 669 1,5 725 1,8 CbiBopoTKa MejioBeKa 43 c HapyuiaiomHMH φ8κτορ3ΜΗ 6790 38 662 1,5
Bce H3MepeHna 6bnw npoBeneHbi npH λ=576 hm h TOJiniHHe cjioa 0,3 cm h nepecHHTaHbi Ha TOJimHHy cjioh d=lcM. a) OnpenejieHHe THpeoTponHHa npH Hcnojib30BaHHH HocHTena peaKTHBOB 1 1
Onpeae;ieHHe THpeoTponHHa πρκ Hcnojib30BaHHH HOCHTejm peaKTHBOB 1 c nojiHMepoM MAK33-IgG ftjra HeūTpajiH3anHH οπείίΗφΗΗβοκΗχ jum M-Fab-<ļ)parMeHTOB HapyuiaioiHHX φ3κτοροΒ. 2 CTaHaapTHbie τΗρεοτροπΗΗΜ KajiHāpoBaHbi Ha 2. IRP 80/588.
CoflepacaHHe THpeoTponHHa b cbieopoTKe HejioeeKa 43 6biJio ποΛΤΒβρχαεΗΟ c noMombio 3Η3ημ>ή T H TecTa φκρΜΗ “BēpHHrep MaHHxaHM Γμ6Χ” ajih 1,2 Μκε,α/ΜΤ. 3τοτ τεοτ β Ka^ecTBe οπειίΗφΗΗβοκΗΧ peaKTaHTOB co^epaamr HaHeceHHbiH Ha Ty6y aHTHTHpHOTponHH MOHOKJIOHajIbHOrO aHTHTejia H IĪOJĪHKJIOHajIbHblii aMHHOTHHecKHit aHTH-TSH-Fab -POD-KOHbioraT. nocjieflHHii HBJiaeica HHepTHbiM no oTHouieHHio κ HapymaioinHM φ3ΚΤορΒΜ b CbieopoTKe HejioBeKa 43. LV 10538 ΦΟΡΜΥϋΑ Η30ΕΡΕΤΕΗΗΛ 1. Cnoco6 onpe^ejieHHH HMMyHOJionwecKM cBS3WBaeMoro BemecTBa b 6HOJion«ecKofi χηλκοοτη nepBoro Bnaa χοιβοτημχ hjīh jno^eii b b npHcyrcTBHH no MeHbineft Mepe ^Byx cneiiH<ļ)HHecKHx λλη HMMyHOJiorHHecKH cBH3biBaeMoro BemecTBa peaKTHBOB BTOporo BHaa ΧΗΒΟΤΗΜΧ Η B npHCyTCTBHH HHm6HTOpa ĶJIK KOMneHCaiļHH Bpe^HbIX φ3κτοροΒ, onumaiouĻuūai meM, hto &jih KOMneHcamiH Bpen,Hbix φΒκτοροΒ peaKnHOHHyio cMecb nepeMeniHBaioT c 0,1-50 μκγ/μλ ΗβοπεηηφΗΗβοκΗΧ zum HMMyHOJionmecKM CBH3biBaeMoro BemecTBa, BbIBeaeHHbIX H3 MOHOKJIOHajIbHbIX HJIH nOJIHIOIOHa.lbHbIX aHTHTeJI arperaTOB BToporo h/hjth TpeTbero Bima χηβοτηβιχ. 2. Cnoco6 b cooTBeTCTBHH c nyHKTOM 1, onuimaiomuūcn meM, HTO HMMyHOJIOrHHeCKH CBH3bIBaeMbIM BemeCTBOM HBJIHeTCfl nojiMBajieHTHbift aHTnreH, cnem^imecKHMH peaKTHBaMH-aHTHTejia, H3 KOTopbix no MeHbmeH Mepe οληο «bjmctch Fab-mrm F(ab')2-φpaΓMeHτoM, ΗβοπείίΗφΗΗβοκΗΜΗ arperaTaMH ABJiaiOTCfl arperHpoBaHHbie HMMyHorjio6yjiHHbi IgG. 39 3. Cnoco6 no πγΗκτγ 1 hjih 2, onuimajomuucA imm, hto nepeMeuiHBaioT peaKUHOHHyio cMecb c 5-25 μκγ/mji ΗεοπευΗφΗΗεααιχ arperaTOB HMMyHonio6yjiHHa IgG. 4. CnocoO no nyHKry 1 hjih 2, onuimaiouĻuūcA meM, hto nepeMeuiHBaioT peaKiļHOHHyio CMecb c 5-10 mkt/mji ΗεοπειίΗφΗΗεοκΗχ arperaTOB HMMyHorjio6yjiHHa IgG. 5. Cnoco6 no o^HOMy H3 nyHKTOB 2-4, omAUHaiouņiūcA meM, hto ΗβοπεηΗφΗΗεοκπε arperaTbi HMMyHorjio6yjiHHa IgG coctoht H3 HMMyHor;io6yjiHHa IgG η Βτοροίί MaKpoMOJieKyjibi. 6. Cnoco6 no nyHicry 5, otruiimaiouņiūcH meM, hto BTopoft
MaKpoMOJieKyjioii HBJiaiOTca ΗεοπεηΗφΗΗεααιε HMMyHorjio6y^HHbi IgG TpeTberO BHHa XCHBOTHbIX, HecneiiH(ļ)HHeCKHe φρΒΓΜεΗΤΗ HMMyHorjio6yjiHHa IgG, cBoāojHbie οτ Fc^paKUHH, προτεΗΗΗ, nojiHcaxapHflbi hjih /ipyroH pacTBopHMbift b Borte nojiHMep. 7. Cnoco6 no ojiHOMy H3 nyHKTOB 1-6, onuuHawuļuuca meM, hto ΗεοπεΗΗφΗΗβοκκε arperaTbi ΗΜειοτ MOJieKyjiHpHbiH Bec 320000 AajībTOHOB h 6ojiee. 8. Cnoco6 no ojīHOMy H3 π>ήκτοβ 1-6, onvtumuomuūcA meM, hto ΗβοπεηΗφΗΗεοκΗε arperaTbi ΗΜειοτ MOJieicyjiiipHbiH Bec 320000 no 10 MJIH. aajIbTOHOB. 9. Cnocoē no ojiHOMy H3 π>ήκτοβ 1-8, onvumatouņiiicA meM, hto ΗεοπειίΗφκΗεοκΗε arperaTbi nojiyneHbi c noMouibio B03neftcTBH5i bmcokoh TeMnepaTypbi, xHMHHecKoro hjih HeKOBa/ieHTHoro “cuiHBaHHH”. LV 10538 10. Cn0C06 ΠΟ ΟΛΗΟΜΥ H3 ΠγΗΚΓΟΒ 1-9, ΠρΗΗβΜ ΠΟ MeHbUieH Mepe ΟΛΚΗ H3 cnenH<ļ)H4ecKHX peaKTHBOB coeflMHeH c MapKHpyiomeH cy6cTaHiweH h jipyroft 33φΗΚ£ΗροΒ3Η Ha MaTpnne hjih 6noTHHHJiHpoBaH, h onpejiejunoT hjih 3aφHκcHpoBaHHyIO, hjih acconHHpoBaHHyio Ha CBB3tIBaK)IiieM ČHOTHHe npOTeHHe HMMyHOJIOrHHeCKH CBH3aHHyiO HJIH HMMyHOJIOrHHeCKH HeCBH3aHHyiO aKTHBHOCTb, OmAUHmOUĶUŪCR meM, HTO BO BpeMH aHajIH3a B peaKIIHOHHOH CM6CH HMdOTCil ΗβΟΠβηΗφΗΗεοΚΗβ φρ3ΓΜεΗΤΜ HMMyHorjio6yjiHHa b pacTBope. 11. jļHarHocTHHecKoe cpejicTBO κλά onpeaejieHH» HMMyHOJiorHHecKH CBH3biBaeMoro BemecTBa b SHOjiorHHecKoft jkhūkocth nepBoro BHjia χηβοτημχ hjih nejioBeica, cojiepacarnee no MeHbineH Mepe flBa ςπεηΗφΗΗβοκΗΧ λιιη HMMyHOJiorHHecKH cBH3biBaeMoro BemecTBa peaicrHBa BToporo BHjia χηβοτημχ, ηηγη6ητορ juih KOMneHcaiiHH BpeūHbix φΒκτοροΒ, cooTBeTCTByiomee δγφερΗοβ BemecTBO, a Taiace npn Heo6xonHMOcTH Λργτκε ο6μηηο npHMeHaeMbie BcnoMoraTejibHbie BemecTBa, onuiunatoineecsi meM, hto juih KOMneHcanHH BpejiHbix φ3κτοροΒ Hcnojib3yioT 0,1-50 mkt/mji ΗεοπεηηφΗΗεοκΗΧ pjm HMMyHOJiorHHecKH CBB3bIBaeMOrO BemecTBa, BbIBejieHHbIX H3 MOHOKJIOHaJIbHbIX HJIH nojiHKJioHajibHbix aHTHTeji arperaTOB BToporo h/hjih TpeTbero BHiia χηβοτημχ c MOJieKyjiHpHbiMH BecaMH CBbime 320000 najībTOHOB. 12. .JlHarHocTHHecKoe cpencTBO no πγΗκτγ 11, onuumaiouļeeai meM, HTO HMMyHOJIOTHHeCKH C BH 3 bl Bāe M bIM BemeCTBOM HBJIHeTCH nojiHBajieHTHbiH aHTMreH, cneinnļmHecKHMH peaKTHBaMH-aHTHTejia, H3 KOTopbix no MeHbmeii Mepe οληο HBjmeTCH Fab-F(ab')2^parMeHTOM, ΗεοπειίΗφΗΗβοκΗΜΗ arperaTaMH «bjihiotcb arperHpoBaHHbie HM\iyHorjio6yjiHHbi IgG. 41 13. ŪHarHOCTHHecKoe cpejicTBO no nyHKTy 11 hjih 12, ottitimaioineecR meM, hto b KanecrBe ΗβοπεηΗφΗΗβοκΗΧ arperaTOB MMMyHor^o6yjiMHa IgG Hcnojib3yioT cocToamne H3 HMMyHonio6yjiHHa IgG h BTOpoft MaKpoMOJieKyjn>i arperaibi HMMyHonio6yjiHHa IgG. 14. /iHarHOCTH^ecKoe cpencTBO no nyHKTy 13, omjimafoineec* meM, hto BTopoft MaKpoMOJieKynoft hbjihiotch ΗβοπβηΗφΗΗεοκΗβ HMMyHorno6yjiHHbi IgG ipeibero BHjia ϊκηβοτημχ, ΗεοπείίΗφΗΗεαοιε φρΒΓΜβΗΤΜ HMMyHOrJIo6yjīHHa IgG, CB06o^Hbie OT Ρθ-φρ3ΚΙίΗΗ, προτεΗΗΗ, nojiMcaxapHflbi hjih flpyrofi pacTBopHMbift b BO,ne nojiHMep. 15. ^narHocTHHecKoe cpe^ciBO no oflHOMy H3 π>ήκτοβ 11-14, onLimaioineecn meM, hto ^Ba hjih 6ojibiue οπειίΗφΗΗβοκΗχ peaKTHBOB MbiniHHbIX HJIH KpbICHHbIX aHTHTeJI, H3 KOTOpbIX ΠΟ MeHbLLieH Mepe OJIHH peaKTHB HBJiHeTca Fab-F(ab,)2-φpaΓMeHTOM h no MeHbmeH Mepe οληη H3 jlpyrHX peaKTHBOB «BJineTCH coflepacamHM Fc^paKiinio HMMyHorjio6yjiHHOM IgG, h ūo6aBJieHbi roMonojiHMepHbie hjih reTeponojiHMepHbie ΗεοπεηΗφΗΗβααιε arperaTbi HMMyHorjio6yjiHHa IgG hjih IgG/ Fab-HJiH F(ab’>2-arperaTbi c MOJieKyjrapHbiMH BecaMH 6ojiee 320000 aajībTOHOB, npnneM conepacamneca b ΗεοπεηΗφΗΗβααιχ arperaTax HMMyHOnio6yjIHHbI IgG H Fab-HJIH F(ab’>2 φρΒΓΜεΗΤΜ MOHOKJIOHaJIbHO H B 3aBHCHMOCTH OT BHJļa H nOflKJiaCCa HBJIHIOTCH ΠΟ MeHbmeH Mepe ΟΛΗΗΜ H3 ΟΠβΙΙΗφΗΗεΟΚΗΧ peaKTHBOB. 16. /jHarHOCTHHecKoe cpejicTBo no 0flH0My H3 π>ήκτοβ 12-15, omnimamneecH meM, hto ΗεοπειίΗφΗΗβοκΗβ arperaTbi HMMyHorjio6yjiHHa IgG HMeioT MojieKyjiapHbiH Bec ot 320000 λο 10 mjih. jļajībTOHOB. LV 10538 17. jļnarHocTHHecKoe cpe^cTBO no οληομυ H3 π>ήκτοβ 12-16, omAMamneecR meM, hto b Ka^ecTBe λοποληητβλβηβιχ BcnoMoraTejibHbix cpencTB Hcnojib3yioTca ycKopHTe;iH peaKiļHH, aeiepreHTbi m/mjim CTa6njiH3aTopbi. LV 10538 AHHOTAIIHfl
YcoBepmeHCTBOBaHHbiH cnoco6 onpeaejieHHH HMMyHOJiorHHecKM cBH3biBaeMoro BemecTBa b npncyTCTBHH no KpaftHeft Mepe £Byx peareHTOB, cnemi4)HHecKHX zuih HMMyHOJion«ecKH cBH3biBaeMoro BemecTBa b npHcyTCTBHH arperHpyeMoro BemecTBa c KOHneHTpaiiHeH 0,1-50 ΜΚΓ/ΜΛΛίΙ KOMneHCanHM BpeflHbIX φΒΚΤΟρΟΒ B npo6aX CbIBOpOTKH nejioBeKa, a TaK xce flHaraocTHHecKoe cpeacTBo, npnroaHoe λλη βτογο cnoco6a.

Claims (17)

  1. LV 10538 IZGUDROJUMA FORMULA 1. Paņēmiens imūnoloģiski saistāmas vielas noteikšanai pirmā veida dzīvnieku vai cilvēka bioloģiskā šķidrumā, ja klāt ir vismaz divi otrā veida dzīvnieku imūnoloģiski saistāmai vielai specifiski reaģenti un inhibitors kaitīgo faktoru kompensācijai, kas atšķiras ar to, ka kaitīgo faktoru kompensācijai, reakcijas maisījumu sajauc ar 0,1-50 pg/ml pret imūnoloģiski saistāmo vielu nespecifiskiem, no otrā un / vai trešā veida dzīvnieku monoklonālajām vai poliklonālajām antivielām izveidotiem agregātiem.
  2. 2. Paņēmiens pēc punkta 1, kas atšķiras ar to, ka imūnoloģiski saistāmā viela ir polivalents antigēns, specifiskie reaģenti-antivielas, no kurām vismaz viena ir Fab- vai F(ab’)2-fragments, bet nespecifiskie agregāti ir agreģēti imūnoglobulīni IgG.
  3. 3. Paņēmiens pēc punkta 1 vai 2, kas atšķiras ar to, ka reakcijas maisījumu sajauc ar 5-25 pg/ml nespecifiskiem imūnoglobulīna IgG agregātiem. 1
  4. 4. Paņēmiens pēc punkta 1 vai 2, kas atšķiras ar to, ka reakcijas maisījumu sajauc ar 5-25 pg/ml nespecifiskiem imūnoglobulīna IgG agregātiem.
  5. 5. Paņēmiens pēc viena no punktiem 2 - 4, kas atšķiras ar to, ka imūnoglobulīna IgG nespecifiskie agregāti sastāv no imūnoglobulīna IgG un otras makromolekulas.
  6. 6. Paņēmiens pēc punkta 5, kas atšķiras arto, ka otrā makromolekula ir trešā veida dzīvnieku nespecifiskie imūnoglobulīni IgG, frakciju Fc nesaturoši imūnoglobulīna IgG nespecifiskie fragmenti, proteīni, polisaharīdi un cits ūdenī šķīstošs polimērs.
  7. 7. Paņēmiens pēc viena no punktiem 1 - 6, kas atšķiras ar to, ka nespecifisko agregātu molekulmasa ir ne mazāka par 320 000 daltoniem.
  8. 8. Paņēmiens pēc viena no punktiem 1 - 6, kas atšķiras ar to, ka nespecifisko agregātu molekulmasa ir no 320 000 līdz 10 miljoniem daltonu.
  9. 9. Paņēmiens pēc viena no punktiem 1 - 8, kas atšķiras ar to, ka nespecifiskie agregāti ir iegūti ar augstas temperatūras iedarbību, ķīmisko vai nekovalento sašūšanu.
  10. 10. Paņēmiens pēc viena no punktiem 1 - 9, ar vismaz vienu iezīmētu specifisko reaģentu un uz matricas fiksētu vai biotinētu otro specifisko reaģentu, nosakot uz saistošā biotinētā proteīna fiksēto vai asociēto imūnoloģiski saistīto vai nesaistīto aktivitāti, kas atšķiras ar to, ka analīzes laikā reakcijas maisījumā šķīdumā ir klāt imūnoglobulīna nespecifiskie agregāti.
  11. 11. Diagnostikas līdzeklis imūnoloģiski saistāmas vielas noteikšanai pirmā veida dzīvnieku vai cilvēka bioloģiskā šķidrumā, ja klāt ir vismaz divi 2 LV 10538 otrā veida dzīvnieku imūnoloģiski saistāmai vielai specifiski reaģenti un inhibitors kaitīgo faktoru kompensācijai, kā arī atbilstoša buferviela un, nepieciešamības gadījumā, citas parasti lietojamās palīgvielas, kas atšķiras ar to, ka kaitīgo faktoru kompensācijai reakcijas maisījumu sajauc ar 0,1-50 pg/ml pret imūnoloģiski saistāmo vielu nespecifiskiem, no otrā un/vai trešā veida dzīvnieku monoklonālajām vai poliklonālajām antivielām izveidotiem agregātiem ar molekulmasu virs 320 000 daltonu.
  12. 12. Diagnostikas līdzeklis pēc punkta 11, kas atšķiras ar to, ka imūnoloģiski saistāmā viela ir polivalents antigēns, specifiski reaģenti -antivielas, no kurām vismaz viena ir Fab-vai F(ab’)2-fragments, bet nespecifiskie agregāti ir agreģēti imūnoglobulīni IgG.
  13. 13. Diagnostikas līdzeklis pēc punkta 11 vai 12 , kas atšķiras ar to, ka tajā par imūnoglobulīna IgG nespecifiskajiem agregātiem izmanto agregātus kas sastāv no imūnoglobulīna IgG un otras makromolekulas.
  14. 14. Diagnostikas līdzeklis pēc punkta 14, kas atšķiras ar to, ka otrā makromolekula ir trešā veida dzīvnieku nespecifiskie imūnoglobulīni IgG, frakciju Fc nesaturoši imūnoglobulīna IgG nespecifiskie fragmenti, proteīni, polisaharīdi un cits ūdenī šķīstošs polimērs.
  15. 15. Diagnostikas līdzeklis pēc viena no punktiem 11-14, kas atšķiras arto, ka tas satur divus vai vairākus specifiskus reaģentus no peļu vai žurku monolonālo antivielu grupas, pie kam vismaz viens no šiem reaģentiem ir Fab-vai F(ab’)2- fragments un vismaz viens no pārējiem reaģentiem ir Fc-frakciju saturošs imūnoglobulīns IgG, un klāt pievienoti nespecifiskie homopolimērie vai heteropolimērie imūnoglobulīna IgG vai IgG/Fab vai F(ab’)2- agregāti ar molekulmasu virs 320000 daltoniem, pie kam nespecifiskajos agregātos ietilpstošie imūnoglobulīni IgG un Fab-vai F(ab’)2- fragmenti ir monoklonāli un atkarībā no veida un apakšklases ir vienādi ar vismaz vienu no specifiskajiem reaģentiem. 3
  16. 16. Diagnostikas līdzeklis pēc viena no punktiem 12-15, kas atšķiras arto, ka imūnoglobulīna IgG nespecifisko agregātu molekulmasa ir no 320 000 līdz 10 000 000 daltonu.
  17. 17. Diagnostikas līdzeklis pēc viena no punktiem 12-16, kas atšķiras arto, ka tajā par papildus palīgvielām tiek izmantoti reakcijas paātrinātāji, deterģenti un/vai stabilizatori. 4
LVP-93-465A 1988-03-03 1993-06-02 Method for testing of immunological binding substance in biological liquid and diagnostically remedy LV10538B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/164,054 US4914040A (en) 1988-03-03 1988-03-03 Reagent and method for determination of a polyvalent substance using an immunoaggregate

Publications (2)

Publication Number Publication Date
LV10538A LV10538A (lv) 1995-02-20
LV10538B true LV10538B (en) 1995-12-20

Family

ID=22592781

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-465A LV10538B (en) 1988-03-03 1993-06-02 Method for testing of immunological binding substance in biological liquid and diagnostically remedy

Country Status (18)

Country Link
US (1) US4914040A (lv)
EP (1) EP0331068B1 (lv)
JP (1) JPH0823560B2 (lv)
AT (1) ATE82072T1 (lv)
AU (1) AU616484B2 (lv)
CA (1) CA1340572C (lv)
DD (1) DD280396A5 (lv)
DE (2) DE3905505A1 (lv)
DK (1) DK175429B1 (lv)
ES (1) ES2045216T3 (lv)
FI (1) FI92879C (lv)
GR (1) GR3006991T3 (lv)
HU (1) HU212322B (lv)
IE (1) IE62974B1 (lv)
LV (1) LV10538B (lv)
PT (1) PT89889B (lv)
RU (1) RU2032906C1 (lv)
ZA (1) ZA891568B (lv)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3730059A1 (de) * 1987-09-08 1989-03-30 Behringwerke Ag Verfahren zur bestimmung von "loeslichem" fibrin
US5141853A (en) * 1988-07-22 1992-08-25 Abbott Laboratories Determination of ammonia levels in a sample
DE3829245A1 (de) * 1988-08-29 1990-03-01 Boehringer Mannheim Gmbh Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
WO1991006559A1 (en) * 1989-10-24 1991-05-16 E.I. Du Pont De Nemours And Company Use of polymerized immunoglobulin to reduce the incidence of false-positive responses in immunoassays
US6274325B1 (en) 1990-06-25 2001-08-14 Boehringer Mannheim Gmbh Method for carrying out a homogeneous-immunoassay based on agglutination
DE4020204A1 (de) * 1990-06-25 1992-01-02 Boehringer Mannheim Gmbh Durchfuehrung eines homogenen immunoassays nach dem agglutinationsprinzip
JPH04350559A (ja) * 1991-05-28 1992-12-04 Dai Ichi Pure Chem Co Ltd 特異抗体の測定法
DE69217957T2 (de) * 1991-07-26 1997-08-07 Dade Chemistry Systems Inc Verfahren zur beseitigung von falschen ergebnissen in einem immunoassay
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
DE4202923A1 (de) * 1992-02-01 1993-08-05 Behringwerke Ag Verfahren zur bestimmung von antigenen oder antikoerpern in gegenwart eines immunkomplexes
IL102495A (en) * 1992-07-14 1998-06-15 Patchornik Avraham Universal standard reagents, method of preparing same and use thereof
IL106887A (en) * 1993-09-02 1997-02-18 Yissum Res Dev Co Pharmaceutical and diagnostic compositions and a method for drug targeting
GB9403215D0 (en) * 1994-02-19 1994-04-13 Kodak Ltd Chemical modification of antibodies and antigens
DE4407423A1 (de) * 1994-03-05 1995-09-07 Boehringer Mannheim Gmbh Entstörmittel zum Einsatz bei Immunoassays
CA2184386C (en) * 1994-03-05 2005-10-18 Rosemarie Kientsch-Engel Interference eliminating agent for application in immunoassays
DE4439452A1 (de) * 1994-11-04 1996-05-09 Boehringer Mannheim Gmbh Antikörperklassenspezifisches Entstörungsreagenz
DE19621133A1 (de) * 1996-05-24 1997-11-27 Boehringer Mannheim Gmbh Bestimmungsverfahren mit oligomerisierten Rezeptoren
DE19731465A1 (de) * 1997-07-22 1999-01-28 Boehringer Mannheim Gmbh Verwendung von Kontrollflächen zur Detektion von Störproben in einem Nachweisverfahren
ATE225511T1 (de) * 1997-12-11 2002-10-15 Roche Diagnostics Gmbh Entstörung von diagnostischen verfahren durch peptide aus d-aminosäuren
DE19828466A1 (de) * 1998-06-26 1999-12-30 Roche Diagnostics Gmbh Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
US6406858B1 (en) * 1998-11-27 2002-06-18 Bayer Corporation System for the reduction of interferences in immunoassays
JP2004510161A (ja) * 2000-09-25 2004-04-02 アボット・ラボラトリーズ 高分子ポリカチオンを用いることにより、特異的結合アッセイにおける血清または血漿含有アッセイ試料の干渉を減少させるための方法及びキット
DE10059720A1 (de) 2000-11-30 2002-06-06 Roche Diagnostics Gmbh Verwendung intramolekular kovalent vernetzter Proteine als Bindepartner in Immunoassays
DE10064827A1 (de) 2000-12-22 2002-06-27 Dade Behring Marburg Gmbh Nachweisverfahren
US20040091952A1 (en) * 2002-07-25 2004-05-13 Sysmex Corporation Reagent kit for detecting lupus anticoagulant
US20040018556A1 (en) * 2002-07-29 2004-01-29 Cantor Thomas L. Reagent and method for determination of a substance using an immunoaggregator
DE602004016906D1 (de) * 2003-03-28 2008-11-20 Sysmex Corp Reagenz zum Nachweis von anti-Phospholipid Antikörper
CN1849514A (zh) * 2003-07-08 2006-10-18 因韦尔尼斯医药瑞士股份有限公司 颗粒凝集的检测方法和装置
US20050112586A1 (en) * 2003-11-24 2005-05-26 Roland Janzen Method and composition for stabilizing liquid reagents
DE602005006633D1 (de) * 2004-02-06 2008-06-26 Sysmex Corp Reagenziensatz zum Nachweis von Lupus-Antikoagulant.
CN1969189B (zh) * 2004-06-14 2012-03-21 协和梅迪克斯株式会社 非特异性反应被抑制的可溶性白介素-2受体免疫学测定方法和试剂
AU2005303388A1 (en) * 2004-11-15 2006-05-18 Inverness Medical Switzerland Gmbh Blood type method system and device
US7172906B2 (en) * 2004-11-16 2007-02-06 Dade Behring Inc. Reduction of non-specific binding in assays
EP2184608B1 (en) * 2007-08-23 2016-10-05 LSI Medience Corporation Non-specific reaction inhibitor
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2019207115A1 (en) * 2018-04-26 2019-10-31 Statens Serum Institut Improved immunoassays
CN109342743B (zh) * 2018-12-05 2022-02-18 菲鹏生物股份有限公司 一种能够与类风湿因子高效结合的变性IgG的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3266967D1 (en) * 1982-01-05 1985-11-21 Int Inst Cellular Molecul Path Method of immunoassay
DE3206729A1 (de) * 1982-02-25 1983-09-01 Behringwerke Ag, 3550 Marburg Immunologisches agglutinationsverfahren
DE3225027A1 (de) * 1982-07-05 1984-01-05 Boehringer Mannheim Gmbh, 6800 Mannheim Immunchemisches messverfahren
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4474892A (en) * 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US4582810A (en) * 1983-09-30 1986-04-15 Becton, Dickinson And Company Immuno-agglutination particle suspensions
JPS60256057A (ja) * 1984-06-01 1985-12-17 Dai Ichi Pure Chem Co Ltd 免疫学的測定法
JPS6165162A (ja) * 1984-09-05 1986-04-03 Chemo Sero Therapeut Res Inst モノクロ−ナル抗体を用いた免疫学的測定方法における非特異反応吸収剤
JPH0799372B2 (ja) * 1985-07-13 1995-10-25 富士レビオ株式会社 逆受身凝集反応用非特異反応吸収剤

Also Published As

Publication number Publication date
FI891012A0 (fi) 1989-03-02
FI92879C (fi) 1995-01-10
JPH0823560B2 (ja) 1996-03-06
PT89889A (pt) 1989-11-10
AU3090889A (en) 1989-09-07
IE62974B1 (en) 1995-03-08
IE890683L (en) 1989-09-03
DE3905505A1 (de) 1989-09-14
DD280396A5 (de) 1990-07-04
EP0331068A1 (de) 1989-09-06
CA1340572C (en) 1999-06-01
LV10538A (lv) 1995-02-20
ATE82072T1 (de) 1992-11-15
RU2032906C1 (ru) 1995-04-10
DE58902586D1 (de) 1992-12-10
PT89889B (pt) 1994-05-31
FI891012A (fi) 1989-09-04
AU616484B2 (en) 1991-10-31
ZA891568B (en) 1989-11-29
DK175429B1 (da) 2004-10-18
GR3006991T3 (lv) 1993-06-30
HUT50988A (en) 1990-03-28
HU212322B (en) 1996-05-28
FI92879B (fi) 1994-09-30
DK96689A (da) 1989-09-04
DK96689D0 (da) 1989-02-28
EP0331068B1 (de) 1992-11-04
ES2045216T3 (es) 1994-01-16
US4914040A (en) 1990-04-03
JPH01254869A (ja) 1989-10-11

Similar Documents

Publication Publication Date Title
LV10538B (en) Method for testing of immunological binding substance in biological liquid and diagnostically remedy
US10761091B2 (en) Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
JP3443891B2 (ja) タンパク質吸着防止剤
CN111417856B (zh) 抑制靶干扰作用的抗药物抗体测定法
KR101353930B1 (ko) 신규한 항원의 검출방법 및 그를 이용한 장치
EP2380593A1 (en) Stabilizing labeled antibody using amino acids
JP4241301B2 (ja) 免疫学的測定用試薬
JP4486059B2 (ja) 免疫測定用ラテックス組成物
WO2019207115A1 (en) Improved immunoassays
Sawant et al. Interaction of aluminum-adjuvanted recombinant P [4] protein antigen with preservatives: Storage stability and backbone flexibility studies
GB1564987A (en) Stable immunological reagents
US11719695B2 (en) Immunoassay method to prevent inhibition of antigen-antibody binding interactions in mucosal fluids
NZ210990A (en) Stabilised enzyme conjugate compositions containing polyethylene glycol
JPH0467150B2 (lv)
Bitsch An investigation into the basic virus-antibody neutralization reaction, with special regard to the reaction in the constant-virus/varying-serum neutralization test
Ogrin et al. Positive test for antithyroglobulin antibodies due to administration of immunoglobulin replacement therapy in a patient with thyroid cancer
US4900684A (en) CEA immunoassay free of human anti-mouse antibody false positives
Zhu-Shimoni et al. Trace level analysis of leached Protein A in bioprocess samples without interference from the large excess of rhMAb IgG
HU et al. Studies on the Optimal Immunization Schedule of Experimental Animals. VI.: Antigen Dose-Response of Aluminum Hydroxide-Aided Immunization and Booster Effect under Low Antigen Dose
JP2015184125A (ja) 非特異的反応を抑制した免疫学的測定方法
US6890711B1 (en) Titration method for a complex viral composition
Soergel et al. Solid-phase radioimmunoassay for detection of plague antigen in animal tissue
JP2545503B2 (ja) 免疫学的診断試薬
JPH1169996A (ja) 発色方法、該方法を用いる酵素免疫測定法及びイムノクロマト法
AU2023254784A1 (en) Complement-dependent cytotoxicity methods.